 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1513
Wor
l
dwi
de 
t
r
ends
 
i
n 
di
abet
es
 
s
i
nc
e 
1980:
 
a 
pool
ed 
anal
ys
i
s
 
of
 
751 
popul
at
i
on-bas
ed 
s
t
udi
es
 
wi
t
h 
4·4 
mi
l
l
i
on 
par
t
i
c
i
pant
s
NCD Ri
s
k Fact
or Col
l
aborat
i
on (
NCD-
Ri
s
C)
*
Summar
y
Bac
kgr
ound One of t
he global t
arget
s for non-communicable diseases is t
o halt
, by 2025, t
he rise in t
he age-
st
andardised adult
 prevalence of diabet
es at
 it
s 201
0 levels.
 We aimed t
o est
imat
e worldwide t
rends in diabet
es, how 
likely it
 is for count
ries t
o achieve t
he global t
arget
, and how changes in prevalence, t
oget
her wit
h populat
ion growt
h 
and ageing, are aff
 ect
ing t
he number of adult
s wit
h diabet
es.
 
Met
hods
 We pooled dat
a from populat
ion-based st
udies t
hat
 had collect
ed dat
a on diabet
es t
hrough measurement
 of 
it
s biomarkers.
 We used a Bayesian hierarchical model t
o est
imat
e t
rends in diabet
es prevalence—defi
 ned as fast
ing 
plasma glucose of 7·0 mmol/L or higher, or hist
ory of diagnosis wit
h diabet
es, or use of insulin or oral hypoglycaemic 
drugs—in 200 count
ries and t
errit
ories in 21
 regions, by sex and from 1
980 t
o 201
4.
 We also calculat
ed t
he post
erior 
probabilit
y of meet
ing t
he global diabet
es t
arget
 if post
-2000 t
rends cont
inue.
Fi
ndi
ngs
 We used dat
a from 751
 st
udies including 4 372 000 adult
s from 1
46 of t
he 200 count
ries we make est
imat
es for.
 
Global age-st
andardised diabet
es prevalence increased from 4·3% (95% credible int
erval 2·4–7·0) in 1
980 t
o 9·0% 
(7·2–1
1
·1
) in 201
4 in men, and from 5·0% (2·9–7·9) t
o 7·9% (6·4–9·7) in women.
 The number of adult
s wit
h diabet
es 
in t
he world increased from 1
08 million in 1
980 t
o 422 million in 201
4 (28·5% due t
o t
he rise in prevalence, 39·7% due 
t
o populat
ion growt
h and ageing, and 31
·8% due t
o int
eract
ion of t
hese t
wo fact
ors).
 Age-st
andardised adult
 diabet
es 
prevalence in 201
4 was lowest
 in nort
hwest
ern Europe, and highest
 in Polynesia and Micronesia, at
 nearly 25%, followed 
by Melanesia and t
he Middle East
 and nort
h Africa.
 Bet
ween 1
980 and 201
4 t
here was lit
t
le change in age-st
andardised 
diabet
es prevalence in adult
 women in cont
inent
al west
ern Europe, alt
hough crude prevalence rose because of ageing 
of t
he populat
ion.
 By cont
rast
, age-st
andardised adult
 prevalence rose by 1
5 percent
age point
s in men and women in 
Polynesia and Micronesia.
 I
n 201
4, American Samoa had t
he highest
 nat
ional prevalence of diabet
es (>30% in bot
h 
sex
es), wit
h age-st
andardised adult
 prevalence also higher t
han 25% in some ot
her islands in Polynesia and Micronesia.
 
I
f post
-2000 t
rends cont
inue, t
he probabilit
y of meet
ing t
he global t
arget
 of halt
ing t
he rise in t
he prevalence of diabet
es 
by 2025 at
 t
he 201
0 level worldwide is lower t
han 1
% for men and is 1
% for women.
 Only nine count
ries for men and 
29 count
ries for women, most
ly in west
ern Europe, have a 50% or higher probabilit
y of meet
ing t
he global t
arget
.
I
nt
er
pr
et
at
i
on Since 1
980, age-st
andardised diabet
es prevalence in adult
s has increased, or at
 best
 remained 
unchanged, in every count
ry.
 Toget
her wit
h populat
ion growt
h and ageing, t
his rise has led t
o a near quadrupling of 
t
he number of adult
s wit
h diabet
es worldwide.
 The burden of diabet
es, bot
h in t
erms of prevalence and number of 
adult
s aff
 ect
ed, has increased fast
er in low-income and middle-income count
ries t
han in high-income count
ries.
Fundi
ng Wellcome Trust
.
Copyr
i
ght
 © NCD Risk Fact
or Collaborat
ion.
 Open Access art
icle dist
ribut
ed under t
he t
erms of CC BY.
I
nt
r
oduc
t
i
on
Di
abetes 
i
s 
an 
i
mportant 
cause 
of 
mortali
ty, 
morbi
di
ty, 
and 
health-system 
costs 
i
n 
the 
world.1,2 
Therefore, 
there 
i
s 
an urgent need to i
mplement populati
on-based i
nter-
venti
ons 
that 
prevent 
di
abetes, 
enhance 
i
ts 
early 
detecti
on, 
and use li
festyle and pharmacologi
cal i
nterventi
ons to 
prevent or delay i
ts progressi
on to compli
cati
ons. To 
moti
vate 
such 
acti
ons, 
one 
of 
the 
global 
targets 
set 
after 
the 
2011 
UN 
Hi
gh-Level 
Meeti
ng 
on 
Non-Communi
cable 
Di
seases 
(NCDs) 
i
s 
to 
halt, 
by 
2025, 
the 
ri
se 
i
n 
the 
age-
standardi
sed adult prevalence of di
abetes at i
ts 2010 
levels.3 Vali
d and consi
stent esti
mates of di
abetes 
prevalence 
over 
ti
me 
are 
needed 
to 
evaluate 
the 
eff
 
ect 
of 
i
nterventi
ons, 
compare 
trends 
i
n 
di
ff
 
erent 
countri
es, 
and 
measure 
progress 
towards 
the 
agreed 
target.
A prev
i
ous study esti
mated trends i
n mean fasti
ng 
plasma 
glucose 
from 
1980 
to 
2008 
and 
reported 
di
abetes 
prev
alence, 
but 
only 
as 
a 
secondary 
outcome 
and 
esti
mated 
based 
on 
mean 
fasti
ng 
plasma 
glucose.4 
The 
Internati
onal 
Di
abetes Federati
on (IDF) peri
odi
cally reports di
abetes 
prev
alence,5,6 but does not analyse trends; uses some 
sources 
that 
are 
based 
solely 
on 
self-reported 
di
abetes; 
and 
does not fully account for di
ff
 
erences i
n di
abetes 
defi
 
ni
ti
ons 
i
n 
di
ff
 
erent 
data 
sources,7 
ev
en 
though 
di
abetes 
prev
alence 
v
ari
es 
dependi
ng 
on 
whether 
i
t 
i
s 
defi
 
ned 
based 
on 
fasti
ng 
plasma 
glucose, 
2 
h 
plasma 
glucose 
i
n 
an 
oral 
glucose tolerance test (2hOGTT), or haemoglobi
n A1c 
(HbA1c).8 Furthermore, i
t i
s not known how trends i
n 
prev
alence, 
together 
wi
th 
populati
on 
growth 
and 
agei
ng, 
hav
e 
aff
 
ected 
the 
number 
of 
adults 
wi
th 
di
abetes. 
Our 
ai
m 
Lanc
et
 
2016; 
387:
 
1513–30
Published 
Onl
i
ne
April 
6, 
2016
ht
t
p://dx.
doi.
org/10.
1016/
S0140-
6736(16)00618-
8
Thi
s
 
onl
i
ne 
publ
i
c
at
i
on 
has
 
been 
c
or
r
ec
t
ed. 
The 
c
or
r
ec
t
ed 
ver
s
i
on 
f
i
r
s
t
 
appear
ed 
at
 
t
hel
anc
et
.c
om 
on 
Oc
t
ober
 
26, 
2016
See 
Comment
 
page 
1485
See 
Per
s
pec
t
i
ves
 
page 
1505
*NCD 
Risk 
Fact
or 
Collaborat
ion 
members 
are 
list
ed 
at
 
t
he 
end 
of 
t
he 
paper
Correspondence 
t
o:
Prof 
Majid 
Ezzat
i, 
School 
of 
Public 
Healt
h, 
Imperial 
College 
London, 
London 
W2 
1PG, 
UK
maji
d.ezzat
i
@i
mper
i
al
.ac
.uk
 Ar
t
i
c
l
es
1514 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
was 
to 
esti
mate 
worldwi
de 
trends 
i
n 
the 
prev
alence 
and 
number of adults wi
th di
abetes. We also esti
mated the 
probabi
li
ty 
of 
achi
ev
i
ng 
the 
global 
di
abetes 
target.
Met
hods
St
udy 
des
i
gn 
and 
defi
 
ni
t
i
ons
We 
esti
mated 
trends 
i
n 
di
abetes 
prevalence 
from 
1980 
to 
2014, i
n 200 countri
es and terri
tori
es organi
sed i
nto 
21 
regi
ons, 
mostly 
on 
the 
basi
s 
of 
geography 
and 
nati
onal 
i
ncome 
(appendi
x 
pp 
11–12). 
The 
excepti
on 
was 
a 
regi
on 
consi
sti
ng of hi
gh-i
ncome Engli
sh-speaki
ng countri
es 
because 
cardi
ometaboli
c 
ri
sk 
factors, 
especi
ally 
body-mass 
i
ndex 
(BMI), 
an 
i
mportant 
ri
sk 
factor 
for 
di
abetes, 
have 
si
mi
lar 
trends 
i
n 
these 
countri
es, 
whi
ch 
can 
be 
di
sti
nct 
from 
other 
countri
es 
i
n 
thei
r 
geographi
cal 
regi
on. 
As 
the 
pri
mary 
outcome, 
di
abetes 
was 
defi
 
ned 
as 
fasti
ng 
plasma 
glucose 
of 
7·0 
mmol/
L 
or 
hi
gher, 
hi
story 
of 
di
agnosi
s 
wi
th 
di
abetes, 
or 
use 
of 
i
nsuli
n 
or 
oral 
hypoglycaemi
c 
drugs. 
Thi
s 
defi
 
ni
ti
on 
of 
di
abetes 
i
s 
used 
i
n 
the 
Global 
Moni
tori
ng 
Framework 
for 
NCDs;3 
i
t 
also 
reli
es 
more 
di
rectly 
on 
data 
from populati
on-based health-exami
nati
on surveys, 
whi
ch, 
for 
logi
sti
cal 
reasons, 
are 
more 
li
kely 
to 
measure 
fasti
ng plasma glucose than 2hOGTT. Our analysi
s 
covered 
men 
and 
women 
aged 
18 
years 
or 
older, 
consi
stent 
wi
th 
the 
Global 
Moni
tori
ng 
Framework 
for 
NCDs.3
Our 
study 
had 
three 
stages, 
each 
descri
bed 
i
n 
detai
l 
below 
and 
i
n 
the 
appendi
x 
(pp 
2–8). 
Fi
rst, 
we 
i
denti
 
fi
 
ed, 
accessed, 
and reanalysed populati
on-based health-exami
nati
on 
surv
eys 
that 
had 
measured 
at 
least 
one 
di
abetes 
bi
omarker. 
We 
then 
conv
erted 
di
abetes 
prev
alence 
i
n 
sources 
that 
had 
defi
 
ned 
di
abetes 
through 
2hOGTT 
or 
HbA1c 
or 
used 
a 
cutoff
 
 
other than 7·0 mmol/
L for fasti
ng plasma glucose, to a 
correspondi
ng 
prev
alence 
based 
on 
the 
pri
mary 
outcome 
as 
defi
 
ned 
abov
e. 
Fi
nally, 
we 
appli
ed 
a 
stati
sti
cal 
model 
to 
the 
pooled 
data 
to 
esti
mate 
trends 
for 
all 
countri
es 
and 
years.
Dat
a 
s
our
c
es
We 
i
ncluded 
data 
sources 
that 
were 
representati
ve 
of 
a 
nati
onal, 
subnati
onal, 
or 
communi
ty 
populati
on 
and 
that 
had measured at least one of the followi
ng di
abetes 
bi
omarkers:
 
fasti
ng 
plasma 
glucose, 
2hOGTT, 
and 
HbA1c. 
We 
di
d 
not 
use 
data 
from 
sources 
that 
reli
ed 
enti
rely 
on 
self-reported 
hi
story 
of 
di
agnosi
s 
because 
thi
s 
approach 
would mi
ss undi
agnosed di
abetes, whi
ch forms a 
substanti
al 
share 
of 
all 
people 
wi
th 
di
abetes, 
especi
ally 
i
n 
communi
ti
es wi
th li
ttle access to health care.9–11 Our 
methods 
for 
i
denti
fyi
ng 
and 
accessi
ng 
data 
sources 
are 
descri
bed 
i
n 
the 
appendi
x 
(pp 
2–6).
Hi
story of di
abetes di
agnosi
s was establi
shed wi
th 
survey-speci
fi
 
c questi
ons, such as “have you ever been 
told 
by 
a 
doctor 
or 
other 
health 
professi
onal 
that 
you 
have 
di
abetes?
” 
or 
the 
combi
nati
on 
of 
“do 
you 
now 
have, 
or 
have you ever had di
abetes?
” and “were you told by a 
doctor that you had di
abetes?
” Si
mi
larly, the use of 
di
abetes drugs was establi
shed wi
th survey-speci
fi
 
c 
questi
ons, 
such 
as 
“are 
you 
currently 
taki
ng 
medi
cati
on 
for 
di
abetes 
or 
hi
gh 
blood 
sugar?
” 
or 
the 
combi
nati
on 
of 
“do 
you 
currently 
i
nject 
i
nsuli
n 
for 
di
abetes?
” 
and 
“are 
you 
currently 
taki
ng 
any 
medi
ci
nes, 
tablets, 
or 
pi
lls 
for 
di
abetes?
” 
Some 
surveys 
also 
veri
fi
 
ed 
medi
cati
ons 
wi
th 
use 
of 
vi
sual 
i
nspecti
on 
or 
medi
cal 
records, 
or 
had 
used 
these 
approaches 
to 
establi
sh 
the 
use 
of 
di
abetes 
drugs.
Conver
s
i
on 
t
o 
a 
c
ons
i
s
t
ent
 
defi
 
ni
t
i
on 
of
 
di
abet
es
9% 
of 
our 
data 
were 
from 
sources 
that 
had 
reported 
the 
prevalence 
of 
di
abetes 
based 
on 
2hOGTT 
or 
HbA1c 
but 
not 
Res
ear
c
h 
i
n 
c
ont
ext
Evi
denc
e 
bef
or
e 
t
hi
s
 
s
t
udy
We 
searched 
MEDLINE 
(via 
PubMed) 
for 
art
icles 
published 
bet
ween 
Jan 
1, 
1950, 
and 
Dec 
11, 
2013, 
wit
h 
t
he 
search 
t
erms 
(“Blood 
Glucose”
[
MAJR] 
OR 
“Diabet
es 
Mellit
us”
[
MAJR:NoExp] 
OR 
“Diabet
es 
Mellit
us, 
Type 
2”
[
MAJR:NoExp] 
OR 
“Diabet
es 
Mellit
us, 
Type 
1”
[
MAJR:NoExp] 
OR 
“Prediabet
ic 
st
at
e”
[
MAJR] 
OR 
“Hyperglycemia”
[
MAJR] 
OR 
“Hemoglobin 
A, 
Glycosylat
ed”
[
MAJR]) 
AND 
(“Humans”
[
Mesh]).
 
Art
icles 
were 
screened 
according 
t
o 
t
he 
inclusion 
and 
exclusion 
crit
eria 
described 
in 
t
he 
appendix 
(pp 
2–6).
A 
few 
st
udies 
have 
report
ed 
diabet
es 
t
rends 
in 
one 
or 
a 
few 
count
ries.
 
A 
previous 
st
udy 
report
ed 
diabet
es 
prevalence 
t
rends 
t
o 
2008 
as 
a 
secondary 
out
come, 
which 
was 
est
imat
ed 
from 
mean 
fast
ing 
plasma 
glucose.
 
This 
st
udy 
was 
done 
before 
t
he 
global 
t
arget
 
on 
diabet
es 
was 
agreed, 
hence 
t
here 
are 
no 
recent
 
dat
a.
 
The 
Int
ernat
ional 
Diabet
es 
Federat
ion 
periodically 
report
s 
diabet
es 
prevalence 
but
 
does 
not
 
analyse 
t
rends, 
uses 
some 
sources 
t
hat
 
are 
only 
based 
on 
self-
report
ed 
diabet
es, 
and 
does 
not
 
fully 
account
 
for 
diff
 
erences 
in 
diabet
es 
defi
 
nit
ions 
in 
diff
 
erent
 
dat
a 
sources.
Added 
val
ue 
of
 
t
hi
s
 
s
t
udy
This 
st
udy 
provides 
t
he 
lengt
hiest
 
and 
most
 
complet
e 
est
imat
es 
of 
t
rends 
in 
adult
 
diabet
es 
prevalence 
worldwide.
 
We 
achieved 
t
his 
level 
of 
det
ail 
by 
reanalysing 
and 
pooling 
hundreds 
of 
populat
ion-
based 
sources 
wit
h 
act
ual 
measurement
s 
of 
at
 
least
 
one 
diabet
es 
biomarker 
and 
syst
emat
ically 
convert
ing 
all 
dat
a 
sources 
t
o 
a 
common 
defi
 
nit
ion 
of 
diabet
es.
 
We 
also 
syst
emat
ically 
project
ed 
recent
 
t
rends 
int
o 
t
he 
fut
ure, 
and 
assessed 
t
he 
probabilit
y 
of 
achieving 
t
he 
global 
diabet
es 
t
arget
.
I
mpl
i
c
at
i
ons
 
of
 
al
l
 
t
he 
avai
l
abl
e 
evi
denc
e
Since 
1980, 
age-
st
andardised 
diabet
es 
prevalence 
in 
adult
s 
increased 
or 
at
 
best
 
remained 
unchanged 
in 
every 
count
ry.
 
The 
burden 
of 
diabet
es, 
in 
t
erms 
of 
bot
h 
prevalence 
and 
number 
of 
adult
s 
aff
 
ect
ed, 
has 
increased 
fast
er 
in 
low-
income 
and 
middle-
income 
count
ries 
t
han 
in 
high-
income 
count
ries.
 
If 
post
-
2000 
t
rends 
cont
inue, 
t
he 
probabilit
y 
of 
meet
ing 
t
he 
global 
diabet
es 
t
arget
 
is 
lower 
t
han 
1% 
for 
men 
and 
is 
1% 
for 
women 
worldwide.
 
See 
Onl
i
ne 
for 
appendix
 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1515
fasti
ng 
plasma 
glucose. 
Another 
29% 
of 
data 
were 
from 
a 
previ
ous 
global 
pooli
ng 
study4 
or 
extracted 
from 
publi
shed 
reports 
and 
papers, 
and 
had 
used 
fasti
ng 
plasma 
glucose 
but reported only mean plasma con 
centrati
ons or a 
prevalence 
based 
on 
a 
cutoff
 
 
other 
than 
7·0 
mmol/
L 
(eg, 
≥7·8 mmol/
L). To correct for i
n 
com 
parabi
li
ty of 
defi
 
ni
ti
ons 
of 
di
abetes, 
we 
used 
regressi
ons 
that 
converted 
prevalence 
from 
these 
sources 
to 
our 
pri
mary 
outcome. 
The dependent vari
able i
n each of these regressi
ons, 
whi
ch 
are 
descri
bed 
i
n 
detai
l 
elsewhere8 
and 
presented 
i
n 
the 
appendi
x 
(pp 
7–8 
and 
30–79), 
was 
the 
pri
mary 
outcome 
(prevalence of fasti
ng plasma glucose ≥7·0 mmol/
L or 
hi
story 
of 
di
abetes 
di
agnosi
s 
or 
use 
of 
di
abetes 
drugs), 
and 
the 
mai
n 
i
ndependent 
vari
able 
was 
a 
prevalence 
based 
on 
the 
defi
 
ni
ti
ons 
i
n 
at 
least 
one 
study 
that 
di
d 
not 
report 
the 
pri
mary 
outcome 
but 
had 
some 
form 
of 
data 
on 
di
abetes 
and 
glycaemi
a. 
The 
coeffi
 
 
ci
ents 
of 
these 
regressi
ons 
were 
esti
mated from data sources wi
th i
ndi
vi
dual-level data, 
whi
ch could be used to calculate prevalence wi
th both 
defi
 
ni
ti
ons. Detai
ls of conversi
on (or cross-walki
ng) 
regressi
ons, 
and 
thei
r 
speci
fi
 
cati
on 
and 
coeffi
 
 
ci
ents, 
are 
presented 
i
n 
the 
appendi
x 
(pp 
30–79). 
Datapoi
nts 
based 
on 
fewer 
than 
25 
people 
were 
excluded. 
All 
regressi
ons 
i
ncluded terms for age, sex, country, i
ncome (natural 
logari
thm 
of 
per-capi
ta 
gross 
domesti
c 
product 
adjusted 
for 
purchasi
ng 
power 
and 
i
nfl
 
ati
on), 
and 
the 
year 
of 
study. 
When 
we 
used 
more 
than 
400 
datapoi
nts 
to 
esti
mate 
the 
regressi
on coeffi
 
 
ci
ents, the regressi
ons also i
ncluded 
regi
onal 
random 
eff
 
ects. 
Fi
nally, 
we 
i
ncluded 
i
nteracti
on 
terms 
i
n 
the 
regressi
ons 
i
f 
the 
i
nteracti
on 
terms 
provi
ded 
a better fi
 
t to the data as determi
ned by the Bayesi
an 
Informati
on 
Cri
teri
on.
St
at
i
s
t
i
c
al
 
anal
ys
i
s
The 
stati
sti
cal 
model 
used 
to 
esti
mate 
di
abetes 
prevalence 
by 
country, 
year, 
age, 
and 
sex 
i
s 
descri
bed 
i
n 
detai
l 
i
n 
a 
stati
sti
cal 
paper 
and 
i
n 
related 
substanti
ve 
papers.12–14 
In 
summary, 
we 
used 
a 
hi
erarchi
cal 
probi
t 
model 
i
n 
whi
ch 
di
abetes levels and trends i
n countri
es were nested i
n 
regi
onal 
levels 
and 
trends, 
whi
ch 
were 
i
n 
turn 
nested 
i
n 
those 
of 
super-regi
ons 
and 
worldwi
de. 
In 
thi
s 
structure, 
esti
mates 
of 
di
abetes 
levels 
and 
trends 
for 
each 
country 
and year were i
nformed by the country’s own data, i
f 
avai
lable, 
and 
by 
data 
from 
other 
years 
i
n 
the 
same 
country 
and i
n other countri
es, especi
ally those i
n the same 
regi
on, 
wi
th 
data 
for 
si
mi
lar 
ti
me 
peri
ods. 
The 
hi
erarchi
cal 
structure 
borrows 
i
nformati
on 
to 
a 
greater 
degree 
when 
data 
are 
non-exi
stent 
or 
weakly 
i
nformati
ve 
(eg, 
because 
they 
have 
a 
small 
sample 
si
ze 
or 
are 
not 
nati
onal), 
and 
to 
a 
lesser 
extent 
i
n 
data-ri
ch 
countri
es 
and 
regi
ons.
The model i
ncorporated non-li
near ti
me trends and 
age 
patterns, 
allowi
ng 
the 
age 
pattern 
of 
di
abetes 
to 
vary 
across 
populati
ons 
such 
that 
the 
ri
se 
i
n 
prevalence 
wi
th 
age would be steeper where di
abetes prevalence i
s 
hi
gher.15 
The 
model 
accounted 
for 
the 
fact 
that 
prevalence 
i
n subnati
onal and communi
ty studi
es mi
ght 
systemati
cally di
ff
 
er from nati
onally representati
ve 
surveys, 
and 
also 
tends 
to 
have 
larger 
vari
ati
on 
relati
ve 
to 
the 
true 
values 
than 
nati
onal 
studi
es 
do. 
These 
features 
were 
i
mplemented 
by 
i
ncludi
ng 
data-dri
ven 
fi
 
xed-eff
 
ect 
and 
random-eff
 
ect 
terms 
for 
subnati
onal 
and 
communi
ty 
data. 
The 
fi
 
xed 
eff
 
ects 
adjust 
for 
systemati
c 
di
ff
 
erences 
between 
sub 
nati
onal 
or 
communi
ty 
studi
es 
and 
nati
onal 
studi
es. 
The 
random 
eff
 
ects 
allow 
nati
onal 
data 
to 
have 
larger i
nfl
 
uence on the esti
mates than subnati
onal or 
communi
ty 
data 
wi
th 
si
mi
lar 
sample 
si
zes. 
The 
model 
also accounted for rural–urban di
ff
 
erences i
n di
abetes 
prevalence, 
through 
the 
use 
of 
data-dri
ven 
fi
 
xed 
eff
 
ects 
for 
rural-only 
and 
urban-only 
studi
es. 
These 
rural 
and 
urban 
eff
 
ects 
were 
wei
ghted 
by 
the 
di
ff
 
erence 
between 
study-level 
and 
country-level 
urbani
sati
on. 
The 
stati
sti
cal 
model also i
ncluded country-level covari
ates that help 
predi
ct 
di
abetes 
prevalence, 
i
ncludi
ng 
average 
number 
of 
years of educati
on, proporti
on of nati
onal populati
on 
li
vi
ng 
i
n 
urban 
areas, 
a 
summary 
measure 
of 
avai
labi
li
ty 
of 
di
ff
 
erent 
food 
types 
for 
human 
consumpti
on, 
and 
age-
standardi
sed adult mean BMI.16 The covari
ate on food 
avai
labi
li
ty 
was 
constructed 
from 
the 
food 
balance 
sheets 
of the Food and Agri
culture Organi
zati
on of the UN, 
wi
th 
use 
of 
pri
nci
pal 
component 
analysi
s. 
Detai
ls 
of 
the 
vari
ables, 
data, 
and 
methods 
are 
provi
ded 
elsewhere.13,17
We 
fi
 
tted 
thi
s 
Bayesi
an 
model 
wi
th 
the 
Markov 
chai
n 
Monte Carlo (MCMC) algori
thm. Convergence was 
moni
tored 
and 
5000 
post-burn-i
n 
samples 
were 
obtai
ned 
from the posteri
or di
stri
buti
on of model parameters, 
whi
ch 
were 
then 
used 
to 
obtai
n 
the 
posteri
or 
di
stri
buti
ons 
of di
abetes prevalence. The reported credi
ble i
ntervals 
(CrI) 
represent 
the 
2·5–97·5 
percenti
les 
of 
the 
posteri
or 
di
stri
buti
ons.
We 
report 
the 
posteri
or 
probabi
li
ty 
that 
an 
esti
mated 
i
ncrease or decrease represents a truly i
ncreasi
ng or 
decreasi
ng 
trend. 
Posteri
or 
probabi
li
ty 
would 
be 
0·50 
i
n 
a 
country 
or 
regi
on 
i
n 
whi
ch 
an 
i
ncrease 
i
s 
stati
sti
cally 
i
ndi
sti
ngui
shable from a decrease; a larger posteri
or 
probabi
li
ty i
ndi
cates more certai
nty i
n a change i
n 
prevalence. Addi
ti
onally, we calculated the posteri
or 
probabi
li
ty 
of 
meeti
ng 
the 
global 
target 
of 
no 
i
ncrease 
i
n 
di
abetes prevalence i
f post-2000 trends conti
nue. All 
analyses 
were 
done 
separately 
by 
sex. 
We 
used 
the 
WHO 
standard 
populati
on 
for 
age 
standardi
sati
on.
We 
exami
ned 
how 
well 
our 
model 
esti
mates 
di
abetes 
prevalence i
n countri
es and years wi
thout data by 
wi
thholdi
ng some of the data from the model and 
calculati
ng the di
ff
 
erences between the held-out data 
and the esti
mates—i
e, the error i
n esti
mates 
(appendi
x 
pp 
9–10). 
Thi
s 
vali
dati
on 
test 
shows 
that 
our 
model 
performed 
very 
well; 
the 
medi
an 
errors 
were 
close 
to zero globally, and the medi
an absolute errors were 
small 
(appendi
x 
pp 
80–84).
Rol
e 
of
 
f
undi
ng 
s
our
c
e
The 
funder 
of 
the 
study 
had 
no 
role 
i
n 
study 
desi
gn, 
data 
collecti
on, 
analysi
s, 
i
nterpretati
on, 
or 
wri
ti
ng 
of 
the report. Country and Regi
onal Data Group 
 Ar
t
i
c
l
es
1516 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
members, 
BZ, 
JB, 
and 
MDC 
had 
full 
access 
to 
the 
data 
i
n 
the 
study 
and 
the 
correspondi
ng 
author 
had 
fi
 
nal 
responsi
bi
li
ty for the deci
si
on to submi
t for 
publi
cati
on.
Res
ul
t
s
We 
used 
data 
from 
751 
populati
on-based 
measurement 
surveys 
and 
studi
es, 
whi
ch 
i
ncluded 
4 
372 
000 
parti
ci
pants 
aged 
18 
years 
or 
older. 
The 
studi
es 
covered 
146 
(73%) 
of 
the 200 countri
es and terri
tori
es for whi
ch esti
mates 
were made (appendi
x pp 97–98). These 146 countri
es 
contai
ned 
90% 
of 
the 
world’s 
adult 
populati
on 
i
n 
2014. 
Regi
onally, the average number of data sources per 
country 
ranged 
from 
less 
than 
one 
i
n 
central 
Afri
ca 
to 
24 
i
n 
the 
hi
gh-i
ncome 
Asi
a 
Paci
fi
 
c 
regi
on. 
21 
(39%) 
of 
the 
54 countri
es wi
thout data were i
n sub-Saharan Afri
ca, 
11 
(20%) 
i
n 
the 
Cari
bbean, 
seven 
(13%) 
i
n 
central 
Europe, 
four 
(7%) 
i
n 
central 
Asi
a, 
and 
the 
remai
ni
ng 
11 
(20%) 
i
n 
other 
regi
ons. 
Nearly 
a 
thi
rd 
of 
surveys 
and 
studi
es 
(242) 
were 
from 
years 
before 
2000, 
and 
the 
other 
two-thi
rds 
(509) 
for 
2000 
and 
later.
From 
1980 
to 
2014, 
worldwi
de 
age-standardi
sed 
adult 
di
abetes prevalence i
ncreased from 4·3% (95% CrI 
2·4–7·0) 
to 
9·0% 
(7·2–11·1) 
i
n 
men 
(fi
 
gure 
1) 
and 
from 
5·0% 
(2·9–7·9) 
to 
7·9% 
(6·4–9·7) 
i
n 
women 
(fi
 
gure 
2); 
the 
posteri
or 
probabi
li
ti
es 
that 
these 
were 
true 
i
ncreases 
were 0·994 and 0·954, respecti
vely. Over these years, 
crude 
adult 
prevalence 
i
ncreased 
from 
3·6% 
(2·0–5·9) 
to 
8·8% (7·0–10·8) i
n men, and from 4·7% (2·7–7·4) to 
8·2% 
(6·6–9·9) 
i
n 
women 
(fi
 
gures 
1, 
2).
Age-standardi
sed di
abetes prevalence i
n women i
n 
2014 was lowest i
n northwestern and south 
western 
Europe, 
whi
ch 
each 
had 
a 
prevalence 
of 
less 
than 
5% 
(fi
 
gure 
2). 
The 
lowest 
prevalence 
i
n 
adult 
men 
was 
also 
i
n northwestern Europe, at 5·8% (95% CrI 3·6–8·7). 
Crude adult prevalence i
n northwestern Europe was 
5·9% (3·8–8·6) for women and 7·9% (5·1–11·5) for 
men i
n 2014. At the other extreme, age-standardi
sed 
di
abetes 
prevalence 
was 
hi
gher 
than 
20% 
i
n 
adult 
men 
and 
women 
i
n 
Polynesi
a 
and 
Mi
cronesi
a, 
and 
around 
15% i
n Melanesi
a and i
n the Mi
ddle East and 
north 
Afri
ca.
Over 
the 
35 
years 
of 
analysi
s, 
there 
was 
almost 
no 
change i
n age-standardi
sed di
abetes prevalence i
n 
women i
n northwestern and southwestern Europe, 
and only a small non-si
gni
fi
 
cant i
ncrease i
n central 
and eastern Europe (fi
 
gure 2). Adult men i
n 
northwestern Europe also had a smaller ri
se i
n 
prevalence than di
d other regi
ons (fi
 
gure 1). By 
contrast, 
age-standardi
sed 
prevalence 
i
n 
Polynesi
a 
and 
Mi
cronesi
a 
rose 
by 
15·0 
(95% 
CrI 
5·5–25·9) 
percentage 
poi
nts 
i
n 
adult 
men 
(posteri
or 
probabi
li
ty 
>0·999) 
and 
by 
14·9 
(4·5–26·2) 
percentage 
poi
nts 
i
n 
adult 
women 
(posteri
or probabi
li
ty 0·998). Crude adult prevalence 
i
ncreased more than age-standardi
sed prevalence i
n 
regi
ons that had substanti
al agei
ng—eg, i
n hi
gh-
i
ncome 
regi
ons.
In 1980, age-standardi
sed adult di
abetes prevalence 
was 
lower 
than 
3% 
i
n 
men 
i
n 
32 
countri
es 
and 
i
n 
women 
i
n 23 countri
es (fi
 
gures 3, 4). In the same year, age-
standardi
sed 
prevalence 
was 
hi
gher 
than 
12% 
i
n 
adult 
men and women i
n a few i
slands i
n Polynesi
a and 
Mi
cronesi
a 
and 
women 
i
n 
Kuwai
t, 
reachi
ng 
25% 
i
n 
men 
and women i
n Nauru. By 2014, women i
n only one 
country 
had 
an 
age-standardi
sed 
adult 
prevalence 
lower 
than 3% and women i
n only ni
ne countri
es had one 
lower 
than 
4%, 
wi
th 
the 
lowest 
prevalence 
esti
mated 
i
n 
some countri
es i
n northwestern Europe such as 
Swi
tzerland, Austri
a, Denmark, Belgi
um, and the 
Netherlands 
(fi
 
gure 
4). 
In 
the 
same 
year, 
age-standardi
sed 
prevalence 
i
n 
adult 
men 
was 
hi
gher 
than 
4% 
i
n 
every 
country 
(fi
 
gure 
3); 
the 
lowest 
esti
mated 
prevalences 
were 
i
n 
the 
same 
northwestern 
European 
countri
es 
as 
those 
for women and i
n a few countri
es i
n east Afri
ca and 
southeast 
Asi
a. 
At 
the 
other 
extreme, 
age-standardi
sed 
adult di
abetes prevalence i
n 2014 was 31% (95% CrI 
19–44) 
i
n 
men 
and 
33% 
(21–47) 
i
n 
women 
i
n 
Ameri
can 
Samoa, and was also hi
gher than 25% i
n men and 
women i
n some other i
slands i
n Polynesi
a and 
Mi
cronesi
a 
(fi
 
gures 
3, 
4; 
appendi
x 
pp 
85–94).
No country had a stati
sti
cally si
gni
fi
 
cant decrease i
n 
di
abetes 
prevalence 
from 
1980 
to 
2014 
(fi
 
gure 
5), 
although 
the 
relati
ve 
i
ncrease 
over 
these 
35 
years 
was 
lower 
than 
20% 
i
n 
ni
ne 
countri
es 
for 
men, 
mostly 
i
n 
northwestern 
Europe, 
and 
i
n 
39 
countri
es 
for 
women. 
Over 
the 
same 
peri
od, 
age-standardi
sed 
adult 
prevalence 
of 
di
abetes 
at 
least 
doubled 
for 
men 
i
n 
120 
countri
es 
and 
for 
women 
i
n 
87 countri
es, wi
th a posteri
or probabi
li
ty of 0·887 or 
hi
gher. 
The 
largest 
absolute 
i
ncreases 
i
n 
age-standardi
sed 
adult prevalence were i
n Oceani
a, exceedi
ng 
15 
percentage 
poi
nts 
i
n 
some 
countri
es, 
followed 
by 
the 
Mi
ddle 
East 
and 
north 
Afri
ca 
(fi
 
gure 
5).
Worldwi
de, i
f post-2000 trends conti
nue, the 
probabi
li
ty of meeti
ng the global di
abetes target for 
men 
i
s 
lower 
than 
1%; 
for 
women 
i
t 
i
s 
1%. 
Only 
ni
ne 
countri
es, 
mostly 
i
n 
northwestern 
Europe, 
had 
a 
50% 
or 
hi
gher 
probabi
li
ty 
of 
meeti
ng 
the 
global 
target 
for 
men, 
as 
di
d 
29 
countri
es 
for 
women 
(fi
 
gure 
6). 
Rather, 
i
f post-2000 trends conti
nue, age-standardi
sed 
prevalence 
of 
di
abetes 
i
n 
2025 
wi
ll 
be 
12·8% 
(95% 
CrI 
8·3–19·6) 
i
n 
men 
and 
10·4% 
(7·1–15·1) 
i
n 
women. 
The 
number 
of 
adults 
wi
th 
di
abetes 
wi
ll 
surpass 
700 
mi
lli
on.
The number of adults wi
th di
abetes i
n the world 
i
ncreased 
from 
108 
mi
lli
on 
i
n 
1980, 
to 
422 
mi
lli
on 
i
n 
2014 
(fi
 
gure 
7). 
East 
Asi
a 
and 
south 
Asi
a 
had 
the 
largest 
ri
ses 
of 
absolute 
numbers, 
and 
had 
the 
largest 
number 
of 
people 
wi
th di
abetes i
n 2014:
 106 mi
lli
on and 86 mi
lli
on, 
respecti
vely. 
39·7% 
(n=124·8 
mi
lli
on) 
of 
the 
ri
se 
i
n 
the 
number 
of 
people 
wi
th 
di
abetes 
was 
due 
to 
populati
on 
growth 
and 
agei
ng, 
28·5% 
(n=89·7 
mi
lli
on) 
due 
to 
the 
ri
se 
i
n 
age-speci
fi
 
c 
prevalences, 
and 
the 
remai
ni
ng 
31·8% 
(n=99·9 
mi
lli
on) 
due 
to 
the 
i
nteracti
on 
of 
the 
two—i
e, 
an 
older and larger populati
on wi
th hi
gher age-speci
fi
 
c 
prevalences 
(fi
 
gure 
7).
 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1517
0
5
10
20
30
15
25
5
10
20
30
15
25
5
10
20
30
15
25
5
10
20
30
15
25
5
10
20
30
15
25
Adult prevalence of diabetes (%)
Adult prevalence of diabetes (%)
Adult prevalence of diabetes (%)
Adult prevalence of diabetes (%)
Adult prevalence of diabetes (%)
Central Asia
0
0
Middle East and north Africa
0
0
5
10
20
30
15
25
Adult prevalence of diabetes (%)
Central Latin America
1980
1990
2000
2010
2014
1985
1995
2005
1980
1990
2000
2010
2014
1985
1995
2005
1980
1990
2000
2010
2014
1985
1995
2005
1980
1990
2000
2010
2014
1985
1995
2005
0
Year
Caribbean
South Asia
West Africa
Andean Latin America
Year
Melanesia
Southeast Asia
Central Africa
Southern Latin America
World
Year
Year
Polynesia and Micronesia
East Asia
East Africa
High-income Asia Pacific
High-income English-speaking 
countries
Northwestern Europe
Southwestern Europe
Central Europe
Eastern Europe
Southern Africa
Age-standardised 
Crude
Fi
gur
e
 
1:
 
Tr
ends
 
i
n 
age-s
t
andar
di
s
ed 
and 
c
r
ude 
pr
eval
enc
e 
of
 
di
abet
es
 
f
or
 
men 
by 
r
egi
on
The 
lines 
(solid 
for 
age-
st
andardised 
and 
dashed 
for 
crude) 
show 
t
he 
post
erior 
mean 
est
imat
es; 
t
he 
shaded 
area 
shows 
t
he 
95% 
credible 
int
ervals 
for 
age-
st
andardised 
prevalence.
 
For 
t
rends 
and 
numerical 
result
s 
by 
count
ry 
see 
appendix 
pp 
85–94, 
103–170.
 Ar
t
i
c
l
es
1518 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
Fi
gur
e 
2:
 
Tr
ends
 
i
n 
age-s
t
andar
di
s
ed 
and 
c
r
ude 
pr
eval
enc
e 
of
 
di
abet
es
 
f
or
 
women 
by 
r
egi
on
The 
lines 
(solid 
for 
age-
st
andardised 
and 
dashed 
for 
crude) 
show 
t
he 
post
erior 
mean 
est
imat
es; 
t
he 
shaded 
area 
shows 
t
he 
95% 
credible 
int
ervals 
for 
age-
st
andardised 
prevalence.
 
For 
t
rends 
and 
numerical 
result
s 
by 
count
ry 
see 
appendix 
pp 
85–94, 
103–170.
0
5
10
20
30
15
25
5
10
20
30
15
25
5
10
20
30
15
25
5
10
20
30
15
25
5
10
20
30
15
25
Adult prevalence of diabetes (%)
Adult prevalence of diabetes (%)
Adult prevalence of diabetes (%)
Adult prevalence of diabetes (%)
Adult prevalence of diabetes (%)
Central Asia
0
0
Middle East and north Africa
0
0
5
10
20
30
15
25
Adult prevalence of diabetes (%)
Central Latin America
1980
1990
2000
2010
2014
1985
1995
2005
1980
1990
2000
2010
2014
1985
1995
2005
1980
1990
2000
2010
2014
1985
1995
2005
1980
1990
2000
2010
2014
1985
1995
2005
0
Year
Caribbean
South Asia
West Africa
Andean Latin America
Year
Melanesia
Southeast Asia
Central Africa
Southern Latin America
World
Year
Year
Polynesia and Micronesia
East Asia
East Africa
High-income Asia Pacific
High-income English-speaking 
countries
Northwestern Europe
Southwestern Europe
Central Europe
Eastern Europe
Southern Africa
Age-standardised
Crude
 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1519
Fi
gur
e 
3 
:
 
Age-s
t
andar
di
s
ed 
pr
eval
enc
e 
of
 
di
abet
es
 
i
n 
adul
t
 
men 
by 
c
ount
r
y 
i
n 
1980 
and 
2014
 Ar
t
i
c
l
es
1520 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
Fi
gur
e 
4:
 
Age-s
t
andar
di
s
ed 
pr
eval
enc
e 
of
 
di
abet
es
 
i
n 
adul
t
 
women 
by 
c
ount
r
y 
i
n 
1980 
and 
2014
 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1521
Half of adults wi
th di
abetes i
n 2014 li
ved i
n fi
 
ve 
countri
es:
 
Chi
na, 
Indi
a, 
the 
USA, 
Brazi
l, 
and 
Indonesi
a 
(fi
 
gure 
8). 
These 
countri
es 
also 
accounted 
for 
one 
half 
of 
the 
world’s 
adult 
populati
on 
i
n 
2014. 
Although 
the 
top 
three 
countri
es 
on 
thi
s 
li
st 
remai
ned 
unchanged 
from 
1980 
to 
2014, 
the 
global 
share 
of 
adults 
wi
th 
di
abetes 
who 
li
ve 
i
n 
Chi
na 
and 
Indi
a 
i
ncreased, 
by 
contrast 
wi
th 
the 
USA, where the share decreased. The changes i
n the 
share 
of 
adults 
wi
th 
di
abetes 
from 
Indi
a 
and 
the 
USA 
mi
ght 
be 
partly 
because 
of 
the 
changes 
i
n 
thei
r 
shares. 
However, the share of the adult populati
on of Chi
na 
remai
ned vi
rtually unchanged, whi
le i
ts share of the 
adult populati
on wi
th di
abetes i
ncreased. Low-i
ncome 
and mi
ddle-i
ncome countri
es, i
ncludi
ng Indonesi
a, 
Paki
stan, Mexi
co, and Egypt, replaced European 
countri
es, i
ncludi
ng Germany, Ukrai
ne, Italy, and the 
UK, 
on 
the 
li
st 
of 
the 
top 
ten 
countri
es 
wi
th 
most 
adults 
wi
th 
di
abetes 
(fi
 
gure 
8).
Di
s
c
us
s
i
on
We 
used 
populati
on-based 
data 
to 
document 
the 
global 
di
abetes epi
demi
c si
nce 1980. Over thi
s peri
od, 
age-standardi
sed 
di
abetes 
prevalence 
i
n 
adults 
i
ncreased 
or 
at 
best 
remai
ned 
unchanged 
i
n 
every 
country. 
It 
more 
than 
doubled 
i
n 
men 
and 
i
ncreased 
by 
60% 
i
n 
women 
worldwi
de, 
shi
fti
ng 
from 
an 
excess 
prevalence 
i
n 
women 
i
n 
1980, 
to 
a 
hi
gher 
male 
prevalence 
i
n 
2014.18,19 
Thi
s 
ri
se 
i
n prevalence has been compounded by populati
on 
growth and agei
ng, nearly quadrupli
ng the number 
of 
adults 
wi
th 
di
abetes 
over 
these 
35 
years. 
The 
burden 
of 
di
abetes, both i
n terms of prevalence and number of 
adults wi
th di
abetes, i
ncreased at a greater rate 
i
n low-i
ncome and mi
ddle-i
ncome countri
es than 
i
n hi
gh-i
ncome countri
es. The hi
ghest nati
onal 
prevalences—generally 
those 
i
n 
Oceani
a, 
and 
the 
Mi
ddle 
East 
and 
north 
Afri
ca—are 
now 
fi
 
ve 
to 
ten 
ti
mes 
greater 
than 
the 
lowest 
prevalences, 
whi
ch 
are 
i
n 
some 
western 
European 
countri
es.
Our 
esti
mates 
of 
di
abetes 
prevalence 
for 
2013 
for 
the 
world 
as 
a 
whole 
are 
si
mi
lar 
to 
those 
by 
the 
IDF 
for 
the 
same year,5,6 but there were di
ff
 
erences between our 
esti
mates 
and 
those 
from 
the 
IDF 
i
n 
some 
countri
es 
and 
regi
ons. In parti
cular, we esti
mated a hi
gher age-
standardi
sed 
prevalence 
of 
di
abetes 
i
n 
most 
countri
es 
i
n 
the 
Mi
ddle 
East 
and 
north 
Afri
ca 
than 
the 
IDF. 
The 
IDF 
does 
not 
esti
mate 
trends, 
hence 
we 
could 
not 
compare 
trend esti
mates. Our fi
 
ndi
ng that di
abetes prevalence 
was 
low 
i
n 
much 
of 
Asi
a 
and 
sub-Saharan 
Afri
ca 
i
n 
the 
1980s and 1990s i
s consi
stent wi
th other studi
es that 
found low prevalences i
n these regi
ons i
n those 
decades.20,21 
Our 
fi
 
ndi
ng 
that 
di
abetes 
prevalence 
di
d 
not 
i
ncrease i
n conti
nental western Europe (especi
ally i
n 
Prevalence at least doubled
Prevalence increased
Prevalence decreased
0
5
10
15
20
25
30
35
0
5
10
15
20
25
30
35
Age-standardised prevalence of diabetes in 2014 (%)
Age-standardised prevalence of diabetes in 1980 (%)
Prevalence at least doubled
Prevalence increased
Prevalence decreased
Men
Women
Age-standardised prevalence of diabetes in 1980 (%)
0
5
10
15
20
25
30
35
Sub-Saharan Africa
Central Asia, Middle East, and north Africa
South Asia
East and southeast Asia
High-income Asia Pacific
Oceania
Latin America and Caribbean
High-income western countries
Central and eastern Europe
World
Fi
gur
e 
5:
 
Compar
i
s
on 
of
 
age-s
t
andar
di
s
ed 
pr
eval
enc
e 
of
 
di
abet
es
 
i
n 
adul
t
s
 
i
n 
1980 
and 
2014
 Ar
t
i
c
l
es
1522 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
Fi
gur
e 
6:
 
Pr
obabi
l
i
t
y 
of
 
ac
hi
evi
ng 
t
he 
t
ar
get
 
of
 
hal
t
i
ng 
t
he 
r
i
s
e 
of
 
di
abet
es
 
i
n 
adul
t
s
 
by 
2025 
at
 
i
t
s
 
2010 
l
evel
s
 
by 
s
ex 
and 
c
ount
r
y 
i
f
 
pos
t
-2000 
t
r
ends
 
c
ont
i
nue
 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1523
northwestern Europe) i
s also consi
stent wi
th reports 
from 
Sweden,22 
Germany,23 
and 
Swi
tzerland24 
that 
covered 
a 
subset 
of 
our 
analysi
s 
years. 
Si
mi
larly, 
our 
esti
mated 
i
ncreases for hi
gh-i
ncome Engli
sh-speaki
ng countri
es 
are 
consi
stent 
wi
th 
studi
es 
that 
had 
analysed 
repeated 
populati
on-based 
surveys 
i
n 
the 
USA25 
and 
the 
UK.26,27 
A 
meta-analysi
s 
of 
15 
studi
es 
i
n 
Japan 
reported 
no 
i
ncrease 
i
n di
abetes prevalence,28 as observed i
n our analysi
s. 
Several recent reports have also documented si
mi
lar 
i
ncreases 
i
n 
di
abetes 
prevalence 
to 
those 
observed 
i
n 
our 
analysi
s 
i
n 
Chi
na,29,30 
Indi
a,31–34 
Iran,35 
Turkey,36 
and 
Saudi
 
Arabi
a.37 
Fi
nally, 
our 
fi
 
ndi
ng 
of 
the 
slower 
ri
se 
i
n 
di
abetes 
prevalence 
i
n 
women 
compared 
wi
th 
men 
i
s 
consi
stent 
wi
th 
hi
stori
cal 
data 
i
n 
a 
few 
hi
gh-i
ncome 
countri
es.18,19
The 
larger 
ri
se 
i
n 
di
abetes 
prev
alence 
i
n 
low-i
ncome 
and 
mi
ddle-i
ncome 
countri
es 
than 
i
n 
hi
gh-i
ncome 
countri
es, 
and the mostly fl
 
at trends i
n Europe (especi
ally i
n 
northwestern 
Europe), 
mi
ght 
be 
caused 
by 
sev
eral 
factors. 
Fi
rst, adi
posi
ty, whi
ch i
s an i
mportant ri
sk factor for 
di
abetes, has i
ncreased substanti
ally more, and i
s now 
hi
gher, 
i
n 
many 
low-i
ncome 
and 
mi
ddle-i
ncome 
countri
es 
than 
i
n 
conti
nental 
Europe 
and 
hi
gh-i
ncome 
Asi
a 
Paci
fi
 
c 
countri
es, especi
ally i
n women.16 Second, regi
onal 
di
ff
 
erences 
i
n 
di
abetes 
could 
be 
due 
i
n 
part 
to 
di
ff
 
erences 
i
n 
geneti
c 
suscepti
bi
li
ty 
or 
phenotypi
c 
v
ari
ati
ons 
ari
si
ng 
from 
i
nadequate 
fetal 
and 
chi
ldhood 
nutri
ti
on 
and 
growth; 
earli
er onset of β-cell dysfuncti
on mi
ght be one 
di
ff
 
erenti
ati
ng characteri
sti
c of Asi
an populati
ons 
compared wi
th European populati
ons.38–42 Thi
rd, better-
resourced health systems i
n Europe and other hi
gh-
i
ncome countri
es mi
ght i
denti
fy people at hi
gh ri
sk of 
di
abetes 
at 
an 
earli
er 
stage, 
and 
use 
li
festyle 
and 
di
etary 
modi
fi
 
cati
on 
or 
drugs 
to 
prev
ent 
or 
delay 
i
ts 
onset.43–45 
At 
the moment, i
nformati
on on the proporti
on of people 
wi
th, 
or 
at 
ri
sk 
of, 
di
abetes 
who 
are 
di
agnosed 
and 
recei
v
e 
treatment i
s li
mi
ted to a few countri
es. Consi
stent 
i
nformati
on on di
agnosi
s and treatment cov
erage wi
ll 
become i
ncreasi
ngly i
mportant as uni
v
ersal health 
cov
erage 
becomes 
a 
central 
theme 
of 
global 
health 
eff
 
orts, 
and should be a focus of future analyses. Fi
nally, i
n 
addi
ti
on to total calori
c i
ntake and adi
posi
ty, di
etary 
composi
ti
on 
and 
physi
cal 
acti
v
i
ty 
mi
ght 
aff
 
ect 
di
abetes 
ri
sk 
and 
contri
bute 
to 
di
ff
 
erences 
i
n 
regi
onal 
trends.46 
These 
and other potenti
al reasons for the di
v
ergent trends i
n 
di
abetes 
prev
alence 
should 
be 
i
nv
esti
gated. 
Furthermore, 
the 
shi
ft 
i
n 
di
abetes 
burden 
from 
women 
towards 
men 
mi
ght 
be 
due 
to 
men 
hav
i
ng 
hi
gher 
prev
alences 
of 
some 
ri
sk 
factors 
for 
di
abetes, 
such 
as 
smoki
ng, 
or 
bei
ng 
at 
ri
sk 
of 
di
abetes 
at 
lower 
BMI 
lev
els 
than 
are 
women.18,19
The 
strengths 
of 
our 
study 
i
nclude 
i
ts 
scope 
of 
maki
ng 
consi
stent 
and 
comparable 
esti
mates 
of 
trends 
i
n 
di
abetes 
prevalence 
and 
of 
the 
probabi
li
ti
es 
of 
meeti
ng 
the 
global 
di
abetes target. We used an unprecedented amount of 
populati
on-based data, whi
ch came from countri
es i
n 
whi
ch 
90% 
of 
the 
global 
adult 
populati
on 
li
ves. 
We 
used 
only data from studi
es that had measured a di
abetes 
bi
omarker 
to 
avoi
d 
bi
as 
i
n 
self-reported 
data. 
Data 
were 
analysed accordi
ng to a common protocol, and the 
characteri
sti
cs 
and 
quali
ty 
of 
data 
sources 
were 
ri
gorously 
veri
fi
 
ed 
through 
repeated 
checks 
by 
Collaborati
ng 
Group 
members from each country. We pooled data usi
ng a 
stati
sti
cal 
model 
that 
took 
i
nto 
account 
the 
epi
demi
ologi
cal 
features 
of 
di
abetes, 
i
ncludi
ng 
non-li
near 
ti
me 
trends 
and 
age 
associ
ati
ons, 
and 
used 
all 
avai
lable 
data 
whi
le 
gi
vi
ng 
Change due to change in prevalence
Change due to interaction between change in prevalence
and change in population size and age structure
Change due to change in population size and age structure
Number of adults with diabetes in 1980  
West Africa
Central Africa
Southern Africa
East Africa
Middle East and north Africa
Central Asia
South Asia
Southeast Asia
East Asia
High-income Asia Pacific
Melanesia
Polynesia and Micronesia
Caribbean
Andean Latin America
Central Latin America
Southern Latin America
High-income English-speaking countries
Northwestern Europe
Southwestern Europe
Central Europe
Eastern Europe
1980
1985
1990
1995
2000
2005
2010
2014
0
50
100
150
200
250
300
350
400
450
500
Number of adults with diabetes (millions)
Year
A
1980
1985
1990
1995
2000
2005
2010
2014
Year
B
Fi
gur
e 
7:
 
Tr
ends
 
i
n 
t
he 
number
 
of
 
adul
t
s
 
wi
t
h 
di
abet
es
 
by 
r
egi
on 
(
A)
 
and 
dec
ompos
ed 
i
nt
o 
t
he 
c
ont
r
i
but
i
ons
 
of
 
popul
at
i
on 
gr
owt
h 
and 
agei
ng, 
r
i
s
e 
i
n 
pr
eval
enc
e, 
and 
i
nt
er
ac
t
i
on 
bet
ween 
t
he 
t
wo 
(
B)
For 
result
s 
by 
region 
see 
appendix 
pp 
101–102.
 Ar
t
i
c
l
es
1524 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
more wei
ght to nati
onal data than to subnati
onal and 
communi
ty 
sources.
Despi
te our extensi
ve eff
 
orts to i
denti
fy and access 
worldwi
de 
populati
on-based 
data, 
some 
countri
es 
had 
no 
or few data sources, especi
ally those i
n sub-Saharan 
Afri
ca, 
the 
Cari
bbean, 
central 
Asi
a, 
and 
central 
Europe. 
Esti
mates 
for 
these 
countri
es 
reli
ed 
mostly 
or 
enti
rely 
on 
the stati
sti
cal model, whi
ch shares i
nformati
on across 
countri
es 
and 
regi
ons 
through 
i
ts 
hi
erarchy 
and 
through 
predi
cti
ve 
covari
ates. 
The 
absence 
or 
scarci
ty 
of 
data 
i
s 
refl
 
ected 
i
n 
wi
der 
uncertai
nty 
i
ntervals 
of 
our 
esti
mates 
for 
these 
countri
es 
and 
regi
ons 
(fi
 
gures 
1, 
2; 
appendi
x 
pp 103–170). Di
abetes was reported usi
ng a defi
 
ni
ti
on 
other 
than 
our 
pri
mary 
outcome 
i
n 
some 
data 
sources, 
ei
ther 
because 
fasti
ng 
plasma 
glucose 
was 
not 
measured 
or 
because 
i
ndi
vi
dual-level 
data 
could 
not 
be 
accessed. 
To 
overcome 
thi
s 
i
ssue, 
we 
systemati
cally 
used 
the 
reported 
metri
cs to esti
mate our pri
mary outcome; the cross-
walki
ng regressi
ons used for thi
s purpose had good 
predi
cti
ve accuracy. The share of studi
es that used a 
portable devi
ce (i
nstead of laboratory analysi
s) for 
measuri
ng 
di
abetes 
bi
omarkers 
has 
i
ncreased 
over 
ti
me. 
We 
do 
not 
expect 
the 
ri
se 
i
n 
the 
use 
of 
portable 
devi
ces 
to 
aff
 
ect the esti
mated levels and trends because thei
r 
hi
gher 
use 
i
n 
populati
on-based 
research 
i
s 
partly 
due 
to 
i
ncreasi
ng 
si
mi
lari
ty 
between 
thei
r 
measurements 
and 
those i
n laboratory-based tests,47,48 faci
li
tated by more 
advanced technologi
es and better standardi
sati
on. 
Further, although our pri
mary outcome i
s consi
stent 
wi
th 
the 
NCD 
Global 
Moni
tori
ng 
Framework, 
di
abetes 
prevalence based on fasti
ng plasma glucose alone i
s 
lower than that based on the combi
nati
on of fasti
ng 
plasma glucose and 2hOGTT.8 Age-standardi
sed adult 
di
abetes 
prevalence 
would 
be 
10·0% 
(95% 
CrI 
8·0–12·5) 
for 
men 
and 
8·8% 
(7·2–10·7) 
for 
women, 
worldwi
de, 
i
f 
we 
appli
ed 
the 
cross-walki
ng 
regressi
on 
(si
mi
lar 
to 
those 
i
n appendi
x pp 34–79) to convert our esti
mates to 
prevalence 
of 
di
abetes 
defi
 
ned 
as 
fasti
ng 
plasma 
glucose 
of 
7·0 
mmol/
L 
or 
hi
gher, 
or 
2hOGTT 
of 
11·1 
mmol/
L 
or 
hi
gher, 
or 
hi
story 
of 
di
agnosi
s 
wi
th 
di
abetes 
or 
use 
of 
i
nsuli
n 
or 
oral 
hypoglycaemi
c 
drugs. 
Fi
nally, 
the 
survey 
data 
di
d 
not 
separate 
type 
1 
and 
type 
2 
di
abetes 
because 
di
sti
ngui
shi
ng between these di
sorders i
s di
ffi
 
 
cult i
n 
adults.49–51 
However, 
most 
(85–95%) 
cases 
of 
di
abetes 
i
n 
adults are type 2,50,52 so the observed ri
se i
n di
abetes 
prevalence 
i
n 
adults 
i
s 
qui
te 
li
kely 
due 
to 
i
ncreases 
i
n 
type 
2 
di
abetes. 
Di
abetes and i
ts macrovascular and mi
crovascular 
compli
cati
ons 
account 
for 
more 
than 
2 
mi
lli
on 
deaths 
every 
year,1 
and 
are 
the 
seventh 
leadi
ng 
cause 
of 
di
sabi
li
ty 
worldwi
de.53 
Di
abetes 
i
s 
also 
a 
ri
sk 
factor 
for 
tuberculosi
s, 
another di
sease wi
th large burden i
n low-i
ncome and 
mi
ddle-i
ncome countri
es.54 Di
abetes and i
ts compli
-
cati
ons 
i
mpose 
substanti
al 
economi
c 
costs 
on 
pati
ents, 
thei
r 
fami
li
es, 
health 
systems, 
and 
nati
onal 
economi
es 
because 
of 
di
rect 
costs 
of 
treatment 
and 
loss 
of 
work 
and 
wages.2 On the basi
s of esti
mates for the number of 
people wi
th di
abetes i
n 2014 i
n thi
s study, and cost 
esti
mates from a systemati
c revi
ew,2 the di
rect annual 
cost of di
abetes i
n the world i
s Intl$825 bi
lli
on, wi
th 
Chi
na ($170 bi
lli
on), the USA ($105 bi
lli
on), Indi
a 
($73 
bi
lli
on), 
and 
Japan 
($37 
bi
lli
on) 
havi
ng 
the 
largest 
2·4 (2·2)
9 Italy
7·1 (6·6)
4 Russia
4·7 (4·4)
5 Japan
20·4 (18·9)
1 China
1·7 (1·6)
15 Mexico
11·9 (11·0)
2 India
3·4 (3·2)
6 Germany
2·7 (2·5)
7 Brazil
2·1 (1·9)
12 Indonesia
1·5 (1·4)
17 Egypt
2·4 (2·2)
8 Ukraine
2·3 (2·1)
10 UK
8·1 (7·5)
3 USA
1·7 (1·6)
13 Pakistan
Millions of adults with diabetes 
(% of global diabetes)
1980
Rank Country
Rank Country
4·3 (1·0)
16 Italy
10·7 (2·5)
8 Russia
10·8 (2·6)
7 Japan
102·9 (24·4)
1 China
8·6 (2·0)
10 Mexico
64·5 (15·3)
2 India
5·1 (1·2)
14 Germany
11·7 (2·8)
4 Brazil
11·7 (2·8)
5 Indonesia
8·6 (2·0)
9 Egypt
3·4 (0·8)
24 Ukraine
3·8 (0·9)
19 UK
22·4 (5·3)
3 USA
11·0 (2·6)
6 Pakistan
Millions of adults with diabetes 
(% of global diabetes)
2014
Fi
gur
e 
8:
 
Ten 
c
ount
r
i
es
 
wi
t
h 
t
he 
l
ar
ges
t
 
number
 
of
 
adul
t
s
 
wi
t
h 
di
abet
es
 
i
n 
1980 
and 
2014
Colours 
for 
each 
count
ry 
indicat
e 
it
s 
region.
 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1525
Mohammed 
K 
Ali
 
(Emory 
Uni
versi
ty, 
USA); 
Cri
sti
na 
Taddei
 
(Uni
versi
ty 
of 
Florence, 
Italy); 
Wei
-Cheng 
Lo 
(Nati
onal 
Tai
wan 
Uni
versi
ty, 
Tai
wan); 
Barbara 
Rei
s-Santos 
(Uni
versi
dade 
Federal 
de 
Pelotas, 
Brazi
l); 
Gretchen 
A 
Stevens 
(World 
Health 
Organi
zati
on, 
Swi
tzerland); 
Leanne 
M 
Ri
ley 
(World 
Health 
Organi
zati
on, 
Swi
tzerland); 
J 
Jai
me 
Mi
randa 
(Uni
versi
dad 
Peruana 
Cayetano 
Heredi
a, 
Peru); 
Prof 
Peter 
Bjerregaard 
(Uni
versi
ty 
of 
Southern 
Denmark, 
Denmark; 
Uni
versi
ty 
of 
Greenland, 
Greenland); 
Prof 
Juan 
A 
Ri
vera 
(Insti
tuto 
Naci
onal 
de 
Salud 
Públi
ca, 
Mexi
co); 
Heba 
M 
Fouad 
(World 
Health 
Organi
zati
on 
Regi
onal 
Offi
 
 
ce 
for 
the 
Eastern 
Medi
terranean, 
Egypt); 
Prof 
Guansheng 
Ma 
(Peki
ng 
Uni
versi
ty, 
Chi
na); 
Prof 
Jean 
Claude 
N 
Mbanya 
(Uni
versi
ty 
of 
Yaoundé 
1, 
Cameroon); 
Prof 
Stephen 
T 
McGarvey 
(Brown 
Uni
versi
ty, 
USA); 
Vi
swanathan 
Mohan 
(Madras 
Di
abetes 
Research 
Foundati
on, 
Indi
a); 
Prof 
Altan 
Onat 
(Istanbul 
Uni
versi
ty, 
Turkey); 
Ai
da 
Pi
lav 
(Federal 
Mi
ni
stry 
of 
Health, 
Bosni
a 
and 
Herzegovi
na); 
Prof 
Ambady 
Ramachandran 
(Indi
a 
Di
abetes 
Research 
Foundati
on, 
Indi
a); 
Prof 
Habi
ba 
Ben 
Romdhane 
(Uni
versi
ty 
Tuni
s 
El 
Manar, 
Tuni
si
a); 
Chri
stopher 
J 
Paci
orek 
(Uni
versi
ty 
of 
Cali
forni
a, 
Berkeley, 
USA); 
James 
E 
Bennett 
(Imperi
al 
College 
London, 
UK); 
Prof 
Maji
d 
Ezzati
 
(Imperi
al 
College 
London, 
UK).
Count
r
y 
and 
Re
gi
onal
 
Dat
a 
(*e
qual
 
c
ont
r
i
but
i
on;
 
l
i
s
t
e
d 
al
phabe
t
i
c
al
l
y)—
Zi
ad 
A 
Abdeen 
(Al-Quds 
Uni
versi
ty, 
Palesti
ne)*; 
Khali
d 
Abdul 
Kadi
r 
(Monash 
Uni
versi
ty 
Malaysi
a, 
Malaysi
a)*; 
Ni
veen 
M 
Abu-Rmei
leh 
(Bi
rzei
t 
Uni
versi
ty, 
Palesti
ne)*; 
Benjami
n 
Acosta-Cazares 
(Insti
tuto 
Mexi
cano 
del 
Seguro 
Soci
al, 
Mexi
co)*; 
Robert 
Adams 
(The 
Uni
versi
ty 
of 
Adelai
de, 
Australi
a)*; 
Wi
chai
 
Aekplakorn 
(Mahi
dol 
Uni
versi
ty, 
Thai
land)*; 
Carlos 
A 
Agui
lar-Sali
nas 
(Insti
tuto 
Naci
onal 
de 
Ci
enci
as 
Médi
cas 
y 
Nutri
ci
on, 
Mexi
co)*; 
Charles 
Agyemang 
(Uni
versi
ty 
of 
Amsterdam, 
Netherlands)*; 
Ali
reza 
Ahmadvand 
(Non-Communi
cable 
Di
seases 
Research 
Center, 
Iran)*; 
Amani
 
Rashed 
Al-Othman 
(Kuwai
t 
Insti
tute 
for 
Sci
enti
fi
 
c 
Research, 
Kuwai
t)*; 
Ala
’a 
Alkerwi
 
(Luxembourg 
Insti
tute 
of 
Health, 
Luxembourg)*; 
Phi
li
ppe 
Amouyel 
(Li
lle 
Uni
versi
ty 
and 
Hospi
tal, 
France)*; 
Antoi
nette 
Amuzu 
(London 
School 
of 
Hygi
ene 
& 
Tropi
cal 
Medi
ci
ne, 
UK)*; 
Lars 
Bo 
Andersen 
(Uni
versi
ty 
of 
Southern 
Denmark, 
Denmark)*; 
Si
gmund 
A 
Anderssen 
(Norwegi
an 
School 
of 
Sport 
Sci
ences, 
Norway)*; 
Ranji
t 
Mohan 
Anjana 
(Madras 
Di
abetes 
Research 
Foundati
on, 
Indi
a)*; 
Hajer 
Aounallah-Skhi
ri
 
(Nati
onal 
Insti
tute 
of 
Publi
c 
Health, 
Tuni
si
a)*; 
Tahi
r 
Ari
s 
(Mi
ni
stry 
of 
Health 
Malaysi
a, 
Malaysi
a)*; 
Ni
mmathota 
Arlappa 
(Indi
an 
Counci
l 
of 
Medi
cal 
Research, 
Indi
a)*; 
Domi
ni
que 
Arvei
ler 
(Strasbourg 
Uni
versi
ty 
and 
Hospi
tal, 
France)*; 
Feli
x 
K 
Assah 
(Uni
versi
ty 
of 
Yaoundé 
1, 
Cameroon)*; 
Mári
a 
Avdi
cová 
(Regi
onal 
Authori
ty 
of 
Publi
c 
Health, 
Banska 
Bystri
ca, 
Slovaki
a)*; 
Ferei
doun 
Azi
zi
 
(Shahi
d 
Beheshti
 
Uni
versi
ty 
of 
Medi
cal 
Sci
ences, 
Iran)*; 
Nagalla 
Balakri
shna 
(Indi
an 
Counci
l 
of 
Medi
cal 
Research, 
Indi
a)*; 
Pi
otr 
Bandosz 
(Medi
cal 
Uni
versi
ty 
of 
Gdansk, 
Poland)*; 
Carlo 
M 
Barbagallo 
(Uni
versi
ty 
of 
Palermo, 
Italy)*; 
Alberto 
Barceló 
(Pan 
Ameri
can 
Health 
Organi
zati
on, 
USA)*; 
Anwar 
M 
Bati
eha 
(Jordan 
Uni
versi
ty 
of 
Sci
ence 
and 
Technology, 
Jordan)*; 
Loui
se 
A 
Baur 
(Uni
versi
ty 
of 
Sydney, 
Australi
a)*; 
Habi
ba 
Ben 
Romdhane 
(Uni
versi
ty 
Tuni
s 
El 
Manar, 
Tuni
si
a)*; 
Mi
khai
l 
Benet 
(Uni
versi
ty 
Medi
cal 
Sci
ence, 
Cuba)*; 
Antoni
o 
Bernabe-Orti
z 
(Uni
versi
dad 
Peruana 
Cayetano 
Heredi
a, 
Peru)*; 
Sumi
t 
Bharadwaj 
(Chi
rayu 
Medi
cal 
College, 
Indi
a)*; 
Santosh 
K 
Bhargava 
(Sunder 
Lal 
Jai
n 
Hospi
tal, 
Indi
a)*; 
Yufang 
Bi
 
(Shanghai
 
Ji
ao-Tong 
Uni
versi
ty 
School 
of 
Medi
ci
ne, 
Chi
na)*; 
Peter 
Bjerregaard 
(Uni
versi
ty 
of 
Southern 
Denmark, 
Denmark; 
Uni
versi
ty 
of 
Greenland, 
Greenland)*; 
Espen 
Bjertness 
(Uni
versi
ty 
of 
Oslo, 
Norway)*; 
Mari
us 
B 
Bjertness 
(Uni
versi
ty 
of 
Oslo, 
Norway)*; 
Ceci
li
a 
Björkelund 
(Uni
versi
ty 
of 
Gothenburg, 
Sweden)*; 
Anneke 
Blokstra 
(Nati
onal 
Insti
tute 
for 
Publi
c 
Health 
and 
the 
Envi
ronment, 
Netherlands)*; 
Si
mona 
Bo 
(Uni
versi
ty 
of 
Turi
n, 
Italy)*; 
Bernhard 
O 
Boehm 
(Nanyang 
Technologi
cal 
Uni
versi
ty, 
Si
ngapore)*; 
Carlos 
P 
Boi
ssonnet 
(Centro 
de 
Educaci
ón 
Médi
ca 
e 
Investi
gaci
ones 
Clí
ni
cas, 
Argenti
na)*; 
Pascal 
Bovet 
(Mi
ni
stry 
of 
Health, 
Seychelles; 
Uni
versi
ty 
of 
Lausanne, 
Swi
tzerland)*; 
Imperi
a 
Brajkovi
ch 
(Uni
versi
dad 
Central 
de 
Venezuela, 
Venezuela)*; 
Juergen 
Breckenkamp 
(Bi
elefeld 
Uni
versi
ty, 
Germany)*; 
Hermann 
Brenner 
(German 
Cancer 
Research 
Center, 
Germany)*; 
Li
zzy 
M 
Brewster 
(Uni
versi
ty 
of 
Amsterdam, 
Netherlands)*; 
Garry 
R 
Bri
an 
(The 
Fred 
Hollows 
Foundati
on 
New 
Zealand, 
New 
Zealand)*; 
Grazi
ella 
Bruno 
(Uni
versi
ty 
of 
Turi
n, 
Italy)*; 
Anna 
Bugge 
(Uni
versi
ty 
of 
Southern 
Denmark, 
costs. 
Nearly 
60% 
of 
the 
global 
costs 
are 
borne 
by 
low-
i
ncome 
and 
mi
ddle-i
ncome 
countri
es, 
where 
substanti
al 
parts of treatment costs are pai
d out-of-pocket,2 whi
ch 
aff
 
ects 
treatment 
uti
li
sati
on 
and 
adherence 
and 
leads 
to 
fi
 
nanci
al 
hardshi
p 
for 
pati
ents 
and 
thei
r 
fami
li
es.
Glucose reducti
on wi
th li
festyle modi
fi
 
cati
on and 
drugs 
i
n 
people 
wi
th 
di
abetes, 
especi
ally 
i
f 
started 
early, 
can 
delay 
progressi
on 
to 
mi
crovascular 
compli
cati
ons.55–57 
Although evi
dence i
s mi
xed from tri
als on the 
macrovascular 
benefi
 
ts 
of 
i
ntensi
ve 
glucose 
loweri
ng,55,58–60 
long-term 
glycaemi
c 
control 
and 
loweri
ng 
blood 
pressure 
and serum cholesterol also reduce the ri
sk of adverse 
cardi
ovascular outcomes.61,62 However, the eff
 
ecti
veness 
of 
these 
i
nterventi
ons 
at 
the 
populati
on 
level 
has 
been 
sli
ght, both because many di
abetes cases remai
n 
undi
agnosed9–11 and because adherence to treatment i
s 
typi
cally lower i
n general populati
ons than i
n those 
enrolled 
i
n 
cli
ni
cal 
tri
als.63–65
Eff
 
orts to reduce the global health and economi
c 
burden of di
abetes should emphasi
se preventi
on of 
di
abetes 
or 
delayi
ng 
i
ts 
onset, 
through 
enhanci
ng 
healthy 
behavi
ours 
and 
di
ets 
at 
the 
populati
on 
level, 
and 
early 
detecti
on and management of hi
gh-ri
sk i
ndi
vi
duals. 
There 
has 
been 
li
ttle 
success 
i
n 
preventi
ng 
obesi
ty,16 
the 
most 
i
mportant 
ri
sk 
factor 
for 
di
abetes, 
at 
the 
populati
on 
level 
although 
the 
global 
target 
on 
obesi
ty 
could 
engender 
new 
eff
 
orts 
and 
poli
cy 
i
nnovati
ons. 
As 
these 
poli
ci
es 
are 
i
mplemented, i
denti
fyi
ng people at hi
gh ri
sk of 
di
abetes—especi
ally those wi
th i
mpai
red glucose 
tolerance—through the pri
mary care system, usi
ng 
advi
ce and support to i
nduce and mai
ntai
n li
festyle 
change, 
possi
bly 
together 
wi
th 
drugs 
such 
as 
metformi
n, 
mi
ght 
be 
the 
only 
short-term 
approach 
for 
global 
di
abetes 
preventi
on.44,64,66,67 Such programmes have been i
mple-
mented i
n a few hi
gh-i
ncome and mi
ddle-i
ncome 
countri
es,45,68,69 but thei
r success elsewhere requi
res a 
fi
 
nanci
ally 
accessi
ble 
pri
mary 
care 
system 
that 
pri
ori
ti
ses 
di
abetes 
preventi
on 
and 
management 
and 
i
s 
staff
 
ed 
and 
resourced 
to 
support 
li
festyle 
change 
and 
i
mprove 
access 
to 
and 
adherence 
to 
medi
cati
on.10,43,45,64,68,70
Cont
r
i
but
or
s
ME 
and 
GD 
desi
gned 
the 
study 
and 
ov
ersaw 
research. 
Members 
of 
the 
Country 
and 
Regi
onal 
Data 
Group 
collected 
and 
reanalysed 
data, 
and 
checked 
pooled 
data 
for 
accuracy 
of 
i
nformati
on 
about 
thei
r 
study 
and 
other 
studi
es 
i
n 
thei
r 
country. 
BZ, 
YL, 
KH, 
and 
MDC 
led 
data 
collecti
on. 
BZ, 
JB, 
and 
YL 
led 
the 
stati
sti
cal 
analysi
s 
and 
prepared 
results. 
Members 
of 
the 
Pooled 
Analysi
s 
and 
Wri
ti
ng 
Group 
collated 
data, 
checked 
all 
data 
sources 
i
n 
consultati
on 
wi
th 
the 
Country 
and 
Regi
onal 
Data 
Group, 
analysed 
pooled 
data, 
and 
prepared 
results. 
ME 
wrote 
the 
fi
 
rst 
draft 
of 
the 
report 
wi
th 
i
nput 
from 
other 
members 
of 
Pooled 
Analysi
s 
and 
Wri
ti
ng 
Group. 
Members 
of 
Country 
and 
Regi
onal 
Data 
Group 
commented 
on 
the 
draft 
report.
NCD 
Ri
s
k 
Fac
t
or
 
Col
l
abor
at
i
on
Pool
e
d 
Anal
ys
i
s
 
and 
Wr
i
t
i
ng 
(*e
qual
 
c
ont
r
i
but
i
on)—Bi
n 
Zhou 
(Imperi
al 
College 
London, 
UK)*; 
Yuan 
Lu 
(Harvard 
T 
H 
Chan 
School 
of 
Publi
c 
Health, 
USA)*; 
Kaveh 
Haji
fathali
an 
(Harvard 
T 
H 
Chan 
School 
of 
Publi
c 
Health, 
USA)*; 
James 
Bentham 
(Imperi
al 
College 
London, 
UK)*; 
Mari
achi
ara 
Di
 
Cesare 
(Imperi
al 
College 
London, 
UK; 
Mi
ddlesex 
Uni
versi
ty, 
UK)*; 
Goodarz 
Danaei
 
(Harvard 
T 
H 
Chan 
School 
of 
Publi
c 
Health, 
USA)*; 
Honor 
Bi
xby 
(Imperi
al 
College 
London, 
UK); 
Melani
e 
J 
Cowan 
(World 
Health 
Organi
zati
on, 
Swi
tzerland); 
 Ar
t
i
c
l
es
1526 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
Denmark)*; 
Antoni
o 
Cabrera 
de 
León 
(Uni
versi
ty 
La 
Laguna, 
Spai
n)*; 
Günay 
Can 
(Istanbul 
Uni
versi
ty, 
Turkey)*; 
Ana 
Paula 
C 
Cândi
do 
(Uni
versi
dade 
Federal 
de 
Jui
z 
de 
Fora, 
Brazi
l)*; 
Vi
ncenzo 
Capuano 
(Cardi
ologi
a 
di
 
Mercato 
S 
Severi
no, 
Italy)*; 
Axel 
C 
Carlsson 
(Karoli
nska 
Insti
tutet, 
Sweden)*; 
Mari
a 
J 
Carvalho 
(Uni
versi
ty 
of 
Porto, 
Portugal)*; 
Feli
pe 
F 
Casanueva 
(Santi
ago 
de 
Compostela 
Uni
versi
ty, 
Spai
n)*; 
Juan-Pablo 
Casas 
(Uni
versi
ty 
College 
London, 
UK)*; 
Carmelo 
A 
Caserta 
(Associ
azi
one 
Calabrese 
di
 
Epatologi
a, 
Italy)*; 
Kati
a 
Castetbon 
(French 
Insti
tute 
for 
Health 
Survei
llance, 
France)*; 
Snehalatha 
Chamukuttan 
(Indi
a 
Di
abetes 
Research 
Foundati
on, 
Indi
a)*; 
Ni
shi
 
Chaturvedi
 
(Uni
versi
ty 
College 
London, 
UK)*; 
Chi
en-Jen 
Chen 
(Academi
a 
Si
ni
ca, 
Tai
wan)*; 
Fangfang 
Chen 
(Capi
tal 
Insti
tute 
of 
Pedi
atri
cs, 
Chi
na)*; 
Shuohua 
Chen 
(Kai
luan 
General 
Hospi
tal, 
Chi
na)*; 
Chi
ng-Yu 
Cheng 
(Duke-NUS 
Graduate 
Medi
cal 
School, 
Si
ngapore)*; 
Angela 
Chetri
t 
(The 
Gertner 
Insti
tute 
for 
Epi
demi
ology 
and 
Health 
Poli
cy 
Research, 
Israel)*; 
Shu-Ti
 
Chi
ou 
(Mi
ni
stry 
of 
Health 
and 
Welfare, 
Tai
wan)*; 
Yumi
 
Cho 
(Korea 
Centers 
for 
Di
sease 
Control 
and 
Preventi
on, 
Republi
c 
of 
Korea)*; 
Jerzy 
Chudek 
(Medi
cal 
Uni
versi
ty 
of 
Si
lesi
a, 
Poland)*; 
Renata 
Ci
fkova 
(Charles 
Uni
versi
ty 
i
n 
Prague, 
Czech 
Republi
c)*; 
Frank 
Claessens 
(Katholi
eke 
Uni
versi
tei
t 
Leuven, 
Belgi
um)*; 
Hans 
Conci
n 
(Agency 
for 
Preventi
ve 
and 
Soci
al 
Medi
ci
ne, 
Austri
a)*; 
Cyrus 
Cooper 
(Uni
versi
ty 
of 
Southampton, 
UK)*; 
Rachel 
Cooper 
(Uni
versi
ty 
College 
London, 
UK)*; 
Si
mona 
Costanzo 
(IRCCS 
Isti
tuto 
Neurologi
co 
Medi
terraneo 
Neuromed, 
Italy)*; 
Domi
ni
que 
Cottel 
(Insti
tut 
Pasteur 
de 
Li
lle, 
France)*; 
Chri
s 
Cowell 
(Westmead 
Uni
versi
ty 
of 
Sydney, 
Australi
a)*; 
Ana 
B 
Crujei
ras 
(CIBEROBN, 
Spai
n)*; 
Grazi
ella 
D’Arri
go 
(Nati
onal 
Counci
l 
of 
Research, 
Italy)*; 
Jean 
Dallongevi
lle 
(Insti
tut 
Pasteur 
de 
Li
lle, 
France)*; 
Rachel 
Dankner 
(The 
Gertner 
Insti
tute 
for 
Epi
demi
ology 
and 
Health 
Poli
cy 
Research, 
Israel)*; 
Luc 
Dauchet 
(Li
lle 
Uni
versi
ty 
Hospi
tal, 
France)*; 
Gi
ovanni
 
de 
Gaetano 
(IRCCS 
Isti
tuto 
Neurologi
co 
Medi
terraneo 
Neuromed, 
Italy)*; 
Stefaan 
De 
Henauw 
(Ghent 
Uni
versi
ty, 
Belgi
um)*; 
Mohan 
Deepa 
(Madras 
Di
abetes 
Research 
Foundati
on, 
Indi
a)*; 
Abbas 
Dehghan 
(Erasmus 
Medi
cal 
Center 
Rotterdam, 
Netherlands)*; 
Valeri
e 
Deschamps 
(French 
Insti
tute 
for 
Health 
Survei
llance, 
France)*; 
Klodi
an 
Dhana 
(Erasmus 
Medi
cal 
Center 
Rotterdam, 
Netherlands)*; 
Augusto 
F 
Di
 
Castelnuovo 
(IRCCS 
Isti
tuto 
Neurologi
co 
Medi
terraneo 
Neuromed, 
Italy)*; 
Shi
ri
n 
Djalali
ni
a 
(Non-
Communi
cable 
Di
seases 
Research 
Center, 
Iran)*; 
Kouamelan 
Doua 
(Mi
ni
stère 
de 
la 
Santé 
et 
de 
la 
Lutte 
Contre 
le 
Si
da, 
Côte 
d’Ivoi
re)*; 
Wojci
ech 
Drygas 
(The 
Cardi
nal 
Wyszynski
 
Insti
tute 
of 
Cardi
ology, 
Poland)*; 
Yong 
Du 
(Robert 
Koch 
Insti
tute, 
Germany)*; 
Vi
lni
s 
Dzerve 
(Uni
versi
ty 
of 
Latvi
a, 
Latvi
a)*; 
Eruke 
E 
Egbagbe 
(Uni
versi
ty 
of 
Beni
n, 
Ni
geri
a)*; 
Robert 
Eggertsen 
(Uni
versi
ty 
of 
Gothenburg, 
Sweden)*; 
Jali
la 
El 
Ati
 
(Nati
onal 
Insti
tute 
of 
Nutri
ti
on 
and 
Food 
Technology, 
Tuni
si
a)*; 
Roberto 
Elosua 
(Insti
tut 
Hospi
tal 
del 
Mar 
d’Investi
gaci
ons 
Mèdi
ques, 
Spai
n)*; 
Raji
v 
T 
Erasmus 
(Uni
versi
ty 
of 
Stellenbosch, 
South 
Afri
ca)*; 
Ci
hangi
r 
Erem 
(Karadeni
z 
Techni
cal 
Uni
versi
ty, 
Turkey)*; 
Gul 
Ergor 
(Dokuz 
Eylul 
Uni
versi
ty, 
Turkey)*; 
Loui
se 
Eri
ksen 
(Uni
versi
ty 
of 
Southern 
Denmark, 
Denmark)*; 
Jorge 
Escobedo-de 
la 
Peña 
(Insti
tuto 
Mexi
cano 
del 
Seguro 
Soci
al, 
Mexi
co)*; 
Caroli
ne 
H 
Fall 
(Uni
versi
ty 
of 
Southampton, 
UK)*; 
Farshad 
Farzadfar 
(Tehran 
Uni
versi
ty 
of 
Medi
cal 
Sci
ences, 
Iran)*; 
Franci
sco 
J 
Feli
x-Redondo 
(Centro 
de 
Salud 
Vi
llanueva 
Norte, 
Spai
n)*; 
Trevor 
S 
Ferguson 
(The 
Uni
versi
ty 
of 
the 
West 
Indi
es, 
Jamai
ca)*; 
Dani
el 
Fernández-Bergés 
(Hospi
tal 
Don 
Beni
to-Vi
llanueva 
de 
la 
Serena, 
Spai
n)*; 
Mari
ka 
Ferrari
 
(Counci
l 
for 
Agri
cultural 
Research 
and 
Economi
cs, 
Italy)*; 
Catteri
na 
Ferrecci
o 
(Ponti
fi
 
ci
a 
Uni
versi
dad 
Católi
ca 
de 
Chi
le, 
Chi
le)*; 
Edi
th 
JM 
Feskens 
(Wageni
ngen 
Uni
versi
ty, 
The 
Netherlands)*; 
Joseph 
D 
Fi
nn 
(Uni
versi
ty 
of 
Manchester, 
UK)*; 
Bernhard 
Föger 
(Agency 
for 
Preventi
ve 
and 
Soci
al 
Medi
ci
ne, 
Austri
a)*; 
Leng 
Huat 
Foo 
(Uni
versi
ti
 
Sai
ns 
Malaysi
a, 
Malaysi
a)*; 
Ann-Sofi
 
e 
Forslund 
(Luleå 
Uni
versi
ty, 
Sweden)*; 
Heba 
M 
Fouad 
(World 
Health 
Organi
zati
on 
Regi
onal 
Offi
 
 
ce 
for 
the 
Eastern 
Medi
terranean, 
Egypt)*; 
Dami
an 
K 
Franci
s 
(The 
Uni
versi
ty 
of 
the 
West 
Indi
es, 
Jamai
ca)*; 
Mari
a 
do 
Carmo 
Franco 
(Federal 
Uni
versi
ty 
of 
São 
Paulo, 
Brazi
l)*; 
Oscar 
H 
Franco 
(Erasmus 
Medi
cal 
Center 
Rotterdam, 
Netherlands)*; 
Gui
llermo 
Frontera 
(Hospi
tal 
Uni
versi
tari
o 
Son 
Espases, 
Spai
n)*; 
Takuro 
Furusawa 
(Kyoto 
Uni
versi
ty, 
Japan)*; 
Zbi
gni
ew 
Gaci
ong 
(Medi
cal 
Uni
versi
ty 
of 
Warsaw, 
Poland)*; 
Sarah 
P 
Garnett 
(Uni
versi
ty 
of 
Sydney, 
Australi
a)*; 
Jean-Mi
chel 
Gaspoz 
(Geneva 
Uni
versi
ty 
Hospi
tals, 
Swi
tzerland)*; 
Magda 
Gasull 
(CIBER 
en 
Epi
demi
ologí
a 
y 
Salud 
Públi
ca, 
Spai
n)*; 
Loui
se 
Gates 
(Australi
an 
Bureau 
of 
Stati
sti
cs, 
Australi
a)*; 
Johanna 
M 
Gelei
jnse 
(Wageni
ngen 
Uni
versi
ty, 
Netherlands)*; 
Anoosheh 
Ghasemi
an 
(Non-Communi
cable 
Di
seases 
Research 
Center, 
Iran)*; 
Anup 
Ghi
mi
re 
(B 
P 
Koi
rala 
Insti
tute 
of 
Health 
Sci
ences, 
Nepal)*; 
Si
mona 
Gi
ampaoli
 
(Isti
tuto 
Superi
ore 
di
 
Sani
tà, 
Italy)*; 
Francesco 
Gi
anfagna 
(Uni
versi
ty 
of 
Insubri
a, 
Italy)*; 
Jonathan 
Gi
ovannelli
 
(Li
lle 
Uni
versi
ty 
Hospi
tal, 
France)*; 
Aleksander 
Gi
wercman 
(Lund 
Uni
versi
ty, 
Sweden)*; 
Marcela 
Gonzalez 
Gross 
(Uni
versi
dad 
Poli
técni
ca 
de 
Madri
d, 
Spai
n)*; 
Juan 
P 
González 
Ri
vas 
(The 
Andes 
Cli
ni
c 
of 
Cardi
o-Metaboli
c 
Studi
es, 
Venezuela)*; 
Mari
ano 
Bonet 
Gorbea 
(Nati
onal 
Insti
tute 
of 
Hygi
ene, 
Epi
demi
ology 
and 
Mi
crobi
ology, 
Cuba)*; 
Frederi
c 
Gottrand 
(Uni
versi
té 
de 
Li
lle 
2, 
France)*; 
Duš
an 
Grafnetter 
(Insti
tute 
for 
Cli
ni
cal 
and 
Experi
mental 
Medi
ci
ne, 
Czech 
Republi
c)*; 
Tomasz 
Grodzi
cki
 
(Jagi
elloni
an 
Uni
versi
ty 
Medi
cal 
College, 
Poland)*; 
Anders 
Grøntved 
(Uni
versi
ty 
of 
Southern 
Denmark, 
Denmark)*; 
Grabri
ella 
Gruden 
(Uni
versi
ty 
of 
Turi
n, 
Italy)*; 
Dongfeng 
Gu 
(Nati
onal 
Center 
of 
Cardi
ovascular 
Di
seases, 
Chi
na)*; 
Ong 
Peng 
Guan 
(Si
ngapore 
Eye 
Research 
Insti
tute, 
Si
ngapore)*; 
Rami
ro 
Guerrero 
(Uni
versi
dad 
Icesi
, 
Colombi
a)*; 
Idri
s 
Guessous 
(Geneva 
Uni
versi
ty 
Hospi
tals, 
Swi
tzerland)*; 
Andre 
L 
Gui
maraes 
(State 
Uni
versi
ty 
of 
Montes 
Claros, 
Brazi
l)*; 
Laura 
Guti
errez 
(Insti
tute 
for 
Cli
ni
cal 
Eff
 
ecti
veness 
and 
Health 
Poli
cy, 
Argenti
na)*; 
Ian 
R 
Hambleton 
(The 
Uni
versi
ty 
of 
the 
West 
Indi
es, 
Barbados)*; 
Rebecca 
Hardy 
(Uni
versi
ty 
College 
London, 
UK)*; 
Rachakulla 
Hari
 
Kumar 
(Indi
an 
Counci
l 
of 
Medi
cal 
Research, 
Indi
a)*; 
Jun 
Hata 
(Kyushu 
Uni
versi
ty, 
Japan)*; 
Ji
ang 
He 
(Tulane 
Uni
versi
ty, 
USA)*; 
Chri
sti
n 
Hei
demann 
(Robert 
Koch 
Insti
tute, 
Germany)*; 
Sauli
 
Herrala 
(Oulu 
Uni
versi
ty 
Hospi
tal, 
Fi
nland)*; 
Ilpo 
Tapani
 
Hi
htani
emi
 
(Imperi
al 
College 
London, 
UK)*; 
Sai
 
Yi
n 
Ho 
(Uni
versi
ty 
of 
Hong 
Kong, 
Chi
na)*; 
Suzanne 
C 
Ho 
(The 
Chi
nese 
Uni
versi
ty 
of 
Hong 
Kong, 
Chi
na)*; 
Albert 
Hofman 
(Erasmus 
Medi
cal 
Center 
Rotterdam, 
Netherlands)*; 
Claudi
a 
M 
Hormi
ga 
(Fundaci
ón 
Oftalmológi
ca 
de 
Santander, 
Colombi
a)*; 
Bernardo 
L 
Horta 
(Uni
versi
dade 
Federal 
de 
Pelotas, 
Brazi
l)*; 
Lei
la 
Houti
 
(Uni
versi
ty 
of 
Oran 
1, 
Algeri
a)*; 
Chri
sti
na 
Howi
tt 
(The 
Uni
versi
ty 
of 
the 
West 
Indi
es, 
Barbados)*; 
Thei
n 
Thei
n 
Htay 
(Mi
ni
stry 
of 
Health, 
Myanmar)*; 
Aung 
Soe 
Htet 
(Uni
versi
ty 
of 
Oslo, 
Norway)*; 
Maung 
Maung 
Than 
Hti
ke 
(Mi
ni
stry 
of 
Health, 
Myanmar)*; 
Yang 
Hu 
(Harvard 
T 
H 
Chan 
School 
of 
Publi
c 
Health, 
USA)*; 
Abdullati
f 
S 
Hussi
eni
 
(Bi
rzei
t 
Uni
versi
ty, 
Palesti
ne)*; 
Inge 
Huybrechts 
(Internati
onal 
Agency 
for 
Research 
on 
Cancer, 
France)*; 
Nahla 
Hwalla 
(Ameri
can 
Uni
versi
ty 
of 
Bei
rut, 
Lebanon)*; 
Li
ci
a 
Iacovi
ello 
(IRCCS 
Isti
tuto 
Neurologi
co 
Medi
terraneo 
Neuromed, 
Italy)*; 
Anna 
G 
Iannone 
(Cardi
ologi
a 
di
 
Mercato 
S. 
Severi
no, 
Italy)*; 
M 
Mohsen 
Ibrahi
m 
(Cai
ro 
Uni
versi
ty, 
Egypt)*; 
Nayu 
Ikeda 
(Nati
onal 
Insti
tute 
of 
Health 
and 
Nutri
ti
on, 
Japan)*; 
M 
Arfan 
Ikram 
(Erasmus 
Medi
cal 
Center 
Rotterdam, 
Netherlands)*; 
Vi
lma 
E 
Irazola 
(Insti
tute 
for 
Cli
ni
cal 
Eff
 
ecti
veness 
and 
Health 
Poli
cy, 
Argenti
na)*; 
Muhammad 
Islam 
(Aga 
Khan 
Uni
versi
ty, 
Paki
stan)*; 
Masanori
 
Iwasaki
 
(Ni
i
gata 
Uni
versi
ty, 
Japan)*; 
Jeremy 
M 
Jacobs 
(Hadassah 
Uni
versi
ty 
Medi
cal 
Center, 
Israel)*; 
Tazeen 
Jafar 
(Duke-NUS 
Graduate 
Medi
cal 
School, 
Si
ngapore)*; 
Kazi
 
M 
Jami
l 
(Kuwai
t 
Insti
tute 
for 
Sci
enti
fi
 
c 
Research, 
Kuwai
t)*; 
Grazyna 
Jasi
enska 
(Jagi
elloni
an 
Uni
versi
ty 
Medi
cal 
College, 
Poland)*; 
Chao 
Qi
ang 
Ji
ang 
(Uni
versi
ty 
of 
Hong 
Kong, 
Chi
na)*; 
Jost 
B 
Jonas 
(Ruprecht-Karls-Uni
versi
ty 
of 
Hei
delberg, 
Germany)*; 
Pradeep 
Joshi
 
(World 
Health 
Organi
zati
on 
Country 
Offi
 
 
ce, 
Indi
a)*; 
Anthony 
Kafatos 
(Uni
versi
ty 
of 
Crete, 
Greece)*; 
Ofra 
Kalter-Lei
bovi
ci
 
(The 
Gertner 
Insti
tute 
for 
Epi
demi
ology 
and 
Health 
Poli
cy 
Research, 
Israel)*; 
Ami
r 
Kasaei
an 
(Non-Communi
cable 
Di
seases 
Research 
Center, 
Iran)*; 
Joanne 
Katz 
(Johns 
Hopki
ns 
Bloomberg 
School 
of 
Publi
c 
Health, 
USA)*; 
Prabhdeep 
Kaur 
(Nati
onal 
Insti
tute 
of 
Epi
demi
ology, 
Indi
a)*; 
Maryam 
Kavousi
 
(Erasmus 
Medi
cal 
Center 
Rotterdam, 
Netherlands)*; 
Si
rkka 
Kei
nänen-Ki
ukaanni
emi
 
(Oulu 
Uni
versi
ty 
Hospi
tal, 
Fi
nland)*; 
Roya 
Keli
shadi
 
(Research 
Insti
tute 
for 
Pri
mordi
al 
Preventi
on 
of 
Non-
Communi
cable 
Di
sease, 
Iran)*; 
Andre 
P 
Kengne 
(South 
Afri
can 
Medi
cal 
Research 
Counci
l, 
South 
Afri
ca)*; 
Mathi
lde 
Kersti
ng 
(Research 
Insti
tute 
of 
Chi
ld 
Nutri
ti
on, 
Germany)*; 
Yousef 
Saleh 
Khader 
(Jordan 
Uni
versi
ty 
of 
Sci
ence 
and 
Technology, 
Jordan)*; 
Davood 
Khali
li
 
(Shahi
d 
Beheshti
 
Uni
versi
ty 
of 
Medi
cal 
Sci
ences, 
Iran)*; 
Young-Ho 
Khang 
(Seoul 
Nati
onal 
Uni
versi
ty, 
Republi
c 
of 
Korea)*; 
Stefan 
Ki
echl 
(Medi
cal 
Uni
versi
ty 
Innsbruck, 
Austri
a)*; 
Jeongseon 
Ki
m 
(Nati
onal 
Cancer 
Center, 
Republi
c 
of 
Korea)*; 
Patri
ck 
Kolsteren 
(Insti
tute 
of 
Tropi
cal 
Medi
ci
ne, 
Belgi
um)*; 
 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1527
Paul 
Korrovi
ts 
(Tartu 
Uni
versi
ty 
Cli
ni
cs, 
Estoni
a)*; 
Wolfgang 
Kratzer 
(Uni
versi
ty 
Hospi
tal 
Ulm, 
Germany)*; 
Daan 
Kromhout 
(Wageni
ngen 
Uni
versi
ty, 
Netherlands)*; 
Urho 
M 
Kujala 
(Uni
versi
ty 
of 
Jyväskylä, 
Fi
nland)*; 
Krzysztof 
Kula 
(Medi
cal 
Uni
versi
ty 
of 
Łodz, 
Poland)*; 
Catheri
ne 
Kyobutungi
 
(Afri
can 
Populati
on 
and 
Health 
Research 
Center, 
Kenya)*; 
Ti
i
na 
Laati
kai
nen 
(Nati
onal 
Insti
tute 
for 
Health 
and 
Welfare, 
Fi
nland)*; 
Carl 
Lachat 
(Ghent 
Uni
versi
ty, 
Belgi
um)*; 
Youcef 
Lai
d 
(INSP, 
Algeri
a)*; 
Tai
 
Hi
ng 
Lam 
(Uni
versi
ty 
of 
Hong 
Kong, 
Chi
na)*; 
Orlando 
Landrove 
(Mi
ni
steri
o 
de 
Salud 
Públi
ca, 
Cuba)*; 
Vera 
Lanska 
(Insti
tute 
for 
Cli
ni
cal 
and 
Experi
mental 
Medi
ci
ne, 
Czech 
Republi
c)*; 
Georg 
Lappas 
(Sahlgrenska 
Academy, 
Sweden)*; 
Avula 
Laxmai
ah 
(Indi
an 
Counci
l 
of 
Medi
cal 
Research, 
Indi
a)*; 
Catheri
ne 
Leclercq 
(Food 
and 
Agri
culture 
Organi
zati
on, 
Italy)*; 
Jeannette 
Lee 
(Nati
onal 
Uni
versi
ty 
of 
Si
ngapore, 
Si
ngapore)*; 
Jeonghee 
Lee 
(Nati
onal 
Cancer 
Center, 
Republi
c 
of 
Korea)*; 
Terho 
Lehti
mäki
 
(Tampere 
Uni
versi
ty 
Hospi
tal, 
Fi
nland)*; 
Rampal 
Lekhraj 
(Uni
versi
ti
 
Putra 
Malaysi
a, 
Malaysi
a)*; 
Luz 
M 
León-Muñoz 
(Uni
versi
dad 
Autónoma 
de 
Madri
d, 
Spai
n)*; 
Yanpi
ng 
Li
 
(Harvard 
T 
H 
Chan 
School 
of 
Publi
c 
Health, 
USA)*; 
Wei
-Yen 
Li
m 
(Nati
onal 
Uni
versi
ty 
of 
Si
ngapore, 
Si
ngapore)*; 
M 
Fernanda 
Li
ma-Costa 
(Oswaldo 
Cruz 
Foundati
on 
Rene 
Rachou 
Research 
Insti
tute, 
Brazi
l)*; 
Hsi
en-Ho 
Li
n 
(Nati
onal 
Tai
wan 
Uni
versi
ty, 
Tai
wan)*; 
Xu 
Li
n 
(Uni
versi
ty 
of 
Chi
nese 
Academy 
of 
Sci
ences, 
Chi
na)*; 
Lauren 
Li
ssner 
(Uni
versi
ty 
of 
Gothenburg, 
Sweden)*; 
Roberto 
Lorbeer 
(Uni
versi
ty 
Medi
ci
ne 
Grei
fswald, 
Germany)*; 
José 
Eugeni
o 
Lozano 
(Consejerí
a 
de 
Sani
dad 
Junta 
de 
Casti
lla 
y 
León, 
Spai
n)*; 
Dali
a 
Luksi
ene 
(Li
thuani
an 
Uni
versi
ty 
of 
Health 
Sci
ences, 
Li
thuani
a)*; 
Annamari
 
Lundqvi
st 
(Nati
onal 
Insti
tute 
for 
Health 
and 
Welfare, 
Fi
nland)*; 
Per 
Lytsy 
(Uni
versi
ty 
of 
Uppsala, 
Sweden)*; 
Guansheng 
Ma 
(Peki
ng 
Uni
versi
ty, 
Chi
na)*; 
George 
L 
L 
Machado-Coelho 
(Uni
versi
dade 
Federal 
de 
Ouro 
Preto, 
Brazi
l)*; 
Suka 
Machi
 
(The 
Ji
kei
 
Uni
versi
ty 
School 
of 
Medi
ci
ne, 
Japan)*; 
Stefani
a 
Maggi
 
(Nati
onal 
Research 
Counci
l, 
Italy)*; 
Di
anna 
J 
Magli
ano 
(Baker 
IDI 
Heart 
and 
Di
abetes 
Insti
tute, 
Australi
a)*; 
Marci
a 
Makdi
sse 
(Hospi
tal 
Israeli
ta 
Albert 
Ei
nstei
n, 
Brazi
l)*; 
Kodavanti
 
Malli
kharjuna 
Rao 
(Indi
an 
Counci
l 
of 
Medi
cal 
Research, 
Indi
a)*; 
Yanni
s 
Mani
os 
(Harokopi
o 
Uni
versi
ty, 
Greece)*; 
Enzo 
Manzato 
(Uni
versi
ty 
of 
Padova, 
Italy)*; 
Paula 
Margozzi
ni
 
(Ponti
fi
 
ci
a 
Uni
versi
dad 
Católi
ca 
de 
Chi
le, 
Chi
le)*; 
Pedro 
Marques-Vi
dal 
(Lausanne 
Uni
versi
ty 
Hospi
tal, 
Swi
tzerland)*; 
Reynaldo 
Martorell 
(Emory 
Uni
versi
ty, 
USA)*; 
Shari
q 
R 
Masoodi
 
(Sher-i
-Kashmi
r 
Insti
tute 
of 
Medi
cal 
Sci
ences, 
Indi
a)*; 
Elli
si
v 
B 
Mathi
esen 
(Ui
T 
The 
Arcti
c 
Uni
versi
ty 
of 
Norway, 
Norway)*; 
Tandi
 
E 
Matsha 
(Cape 
Peni
nsula 
Uni
versi
ty 
of 
Technology, 
South 
Afri
ca)*; 
Jean 
Claude 
N 
Mbanya 
(Uni
versi
ty 
of 
Yaoundé 
1, 
Cameroon)*; 
Shelly 
R 
McFarlane 
(The 
Uni
versi
ty 
of 
the 
West 
Indi
es, 
Jamai
ca)*; 
Stephen 
T 
McGarvey 
(Brown 
Uni
versi
ty, 
USA)*; 
Stela 
McLachlan 
(Uni
versi
ty 
of 
Edi
nburgh, 
UK)*; 
Brei
ge 
A 
McNulty 
(Uni
versi
ty 
College 
Dubli
n, 
Ireland)*; 
Sounni
a 
Medi
ene-Benchekor 
(Uni
versi
ty 
of 
Oran 
1, 
Algeri
a)*; 
Ali
ne 
Mei
rhaeghe 
(INSERM, 
France)*; 
Ana 
Mari
a 
B 
Menezes 
(Uni
versi
dade 
Federal 
de 
Pelotas, 
Brazi
l)*; 
Shahi
n 
Merat 
(Di
gesti
ve 
Di
sease 
Research 
Insti
tute, 
Iran)*; 
Indrapal 
I 
Meshram 
(Indi
an 
Counci
l 
of 
Medi
cal 
Research, 
Indi
a)*; 
Ji
e 
Mi
 
(Capi
tal 
Insti
tute 
of 
Pedi
atri
cs, 
Chi
na)*; 
Juan 
Franci
sco 
Mi
quel 
(Ponti
fi
 
ci
a 
Uni
versi
dad 
Católi
ca 
de 
Chi
le, 
Chi
le)*; 
J 
Jai
me 
Mi
randa 
(Uni
versi
dad 
Peruana 
Cayetano 
Heredi
a, 
Peru)*; 
Mostafa 
K 
Mohamed 
(Ai
n 
Shams 
Uni
versi
ty, 
Egypt)*; 
Kazem 
Mohammad 
(Tehran 
Uni
versi
ty 
of 
Medi
cal 
Sci
ences, 
Iran)*; 
Noushi
n 
Mohammadi
fard 
(Isfahan 
Cardi
ovascular 
Research 
Center, 
Iran)*; 
Vi
swanathan 
Mohan 
(Madras 
Di
abetes 
Research 
Foundati
on, 
Indi
a)*; 
Muhammad 
Fadhli
 
Mohd 
Yusoff
 
 
(Mi
ni
stry 
of 
Health 
Malaysi
a, 
Malaysi
a)*; 
Ni
els 
C 
Møller 
(Uni
versi
ty 
of 
Southern 
Denmark, 
Denmark)*; 
Dénes 
Molnár 
(Uni
versi
ty 
of 
Pécs, 
Hungary)*; 
Charles 
K 
Mondo 
(Mulago 
Hospi
tal, 
Uganda)*; 
Alai
n 
Morejon 
(Uni
versi
ty 
Medi
cal 
Sci
ence, 
Cuba)*; 
Lui
s 
A 
Moreno 
(Uni
versi
dad 
de 
Zaragoza, 
Spai
n)*; 
Karen 
Morgan 
(RCSI 
Dubli
n, 
Ireland)*; 
George 
Moschoni
s 
(Harokopi
o 
Uni
versi
ty, 
Greece)*; 
Malgorzata 
Mossakowska 
(Internati
onal 
Insti
tute 
of 
Molecular 
and 
Cell 
Bi
ology, 
Poland)*; 
Aya 
Mostafa 
(Ai
n 
Shams 
Uni
versi
ty, 
Egypt)*; 
Jorge 
Mota 
(Uni
versi
ty 
of 
Porto, 
Portugal)*; 
Jorge 
Motta 
(Gorgas 
Memori
al 
Insti
tute 
of 
Publi
c 
Health, 
Panama)*; 
Thet 
Thet 
Mu 
(Department 
of 
Publi
c 
Health, 
Myanmar)*; 
Mari
a 
Lorenza 
Mui
esan 
(Uni
versi
ty 
of 
Bresci
a, 
Italy)*; 
Marti
na 
Müller-Nurasyi
d 
(Helmholtz 
Zentrum 
München, 
Germany)*; 
Jaakko 
Mursu 
(Uni
versi
ty 
of 
Eastern 
Fi
nland, 
Fi
nland)*; 
Gabri
ele 
Nagel 
(Ulm 
Uni
versi
ty, 
Germany)*; 
Jana 
Námeš
ná 
(Regi
onal 
Authori
ty 
of 
Publi
c 
Health, 
Banska 
Bystri
ca, 
Slovaki
a)*; 
Ei
 
Ei
 
K 
Nang 
(Nati
onal 
Uni
versi
ty 
of 
Si
ngapore, 
Si
ngapore)*; 
Vi
nay 
B 
Nangi
a 
(Suraj 
Eye 
Insti
tute, 
Indi
a)*; 
Eva 
Mari
a 
Navarrete-Muñoz 
(CIBER 
en 
Epi
demi
ologí
a 
y 
Salud 
Públi
ca, 
Spai
n)*; 
Ndeye 
Coumba 
Ndi
aye 
(INSERM, 
France)*; 
Ilona 
Nenko 
(Jagi
elloni
an 
Uni
versi
ty 
Medi
cal 
College, 
Poland)*; 
Flavi
o 
Nervi
 
(Ponti
fi
 
ci
a 
Uni
versi
dad 
Católi
ca 
de 
Chi
le, 
Chi
le)*; 
Nguyen 
D 
Nguyen 
(Uni
versi
ty 
of 
Pharmacy 
and 
Medi
ci
ne 
of 
Ho 
Chi
 
Mi
nh 
Ci
ty, 
Vi
etnam)*; 
Quang 
Ngoc 
Nguyen 
(Hanoi
 
Medi
cal 
Uni
versi
ty, 
Vi
etnam)*; 
Ramfi
 
s 
E 
Ni
eto-Martí
nez 
(Uni
versi
dad 
Centro-Occi
dental 
Li
sandro 
Alvarado, 
Venezuela)*; 
Guang 
Ni
ng 
(Shanghai
 
Ji
ao-Tong 
Uni
versi
ty 
School 
of 
Medi
ci
ne, 
Chi
na)*; 
Toshi
haru 
Ni
nomi
ya 
(Kyushu 
Uni
versi
ty, 
Japan)*; 
Mari
anna 
Noale 
(Nati
onal 
Research 
Counci
l, 
Italy)*; 
Davi
de 
Noto 
(Uni
versi
ty 
of 
Palermo, 
Italy)*; 
Mohannad 
Al 
Nsour 
(Eastern 
Medi
terranean 
Publi
c 
Health 
Network, 
Jordan)*; 
Angéli
ca 
M 
Ochoa-Avi
lés 
(Uni
versi
dad 
de 
Cuenca, 
Ecuador)*; 
Kyungwon 
Oh 
(Korea 
Centers 
for 
Di
sease 
Control 
and 
Preventi
on, 
Republi
c 
of 
Korea)*; 
Altan 
Onat 
(Istanbul 
Uni
versi
ty, 
Turkey)*; 
Pedro 
Ordunez 
(Pan 
Ameri
can 
Health 
Organi
zati
on, 
USA)*; 
Cli
ve 
Osmond 
(MRC 
Li
fecourse 
Epi
demi
ology 
Uni
t, 
UK)*; 
Johanna 
A 
Otero 
(Fundaci
ón 
Oftalmológi
ca 
de 
Santander, 
Colombi
a)*; 
Elli
s 
Owusu-Dabo 
(Kwame 
Nkrumah 
Uni
versi
ty 
of 
Sci
ence 
and 
Technology, 
Ghana)*; 
Elena 
Pahomova 
(Uni
versi
ty 
of 
Latvi
a, 
Latvi
a)*; 
Lui
gi
 
Palmi
eri
 
(Isti
tuto 
Superi
ore 
di
 
Sani
tà, 
Italy)*; 
Songhomi
tra 
Panda-Jonas 
(Ruprecht-Karls-Uni
versi
ty 
of 
Hei
delberg, 
Germany)*; 
Francesco 
Panza 
(Uni
versi
ty 
of 
Bari
, 
Italy)*; 
Mahboubeh 
Parsaei
an 
(Non-Communi
cable 
Di
seases 
Research 
Center, 
Iran)*; 
Sergi
o 
Vi
ana 
Pei
xoto 
(Oswaldo 
Cruz 
Foundati
on 
Rene 
Rachou 
Research 
Insti
tute, 
Brazi
l)*; 
Catheri
ne 
Pelleti
er 
(Publi
c 
Health 
Agency 
of 
Canada, 
Canada)*; 
Markku 
Peltonen 
(Nati
onal 
Insti
tute 
for 
Health 
and 
Welfare, 
Fi
nland)*; 
Annette 
Peters 
(Helmholtz 
Zentrum 
München, 
Germany)*; 
Ni
loofar 
Peykari
 
(Non-Communi
cable 
Di
seases 
Research 
Center, 
Iran)*; 
Son 
Thai
 
Pham 
(Vi
etnam 
Nati
onal 
Heart 
Insti
tute, 
Vi
etnam)*; 
Ai
da 
Pi
lav 
(Federal 
Mi
ni
stry 
of 
Health, 
Bosni
a 
and 
Herzegovi
na)*; 
Freda 
Pi
takaka 
(Uni
versi
ty 
of 
New 
South 
Wales, 
Australi
a)*; 
Aleksandra 
Pi
wonska 
(The 
Cardi
nal 
Wyszynski
 
Insti
tute 
of 
Cardi
ology, 
Poland)*; 
Jerzy 
Pi
wonski
 
(The 
Cardi
nal 
Wyszynski
 
Insti
tute 
of 
Cardi
ology, 
Poland)*; 
Pedro 
Plans-Rubi
ó 
(Publi
c 
Health 
Agency 
of 
Cataloni
a, 
Spai
n)*; 
Mi
quel 
Porta 
(Insti
tut 
Hospi
tal 
del 
Mar 
d’Investi
gaci
ons 
Mèdi
ques, 
Spai
n)*; 
Mari
leen 
L 
P 
Portegi
es 
(Erasmus 
Medi
cal 
Center 
Rotterdam, 
Netherlands)*; 
Hossei
n 
Poustchi
 
(Tehran 
Uni
versi
ty 
of 
Medi
cal 
Sci
ences, 
Iran)*; 
Rajendra 
Pradeepa 
(Madras 
Di
abetes 
Research 
Foundati
on, 
Indi
a)*; 
Jacqueli
ne 
F 
Pri
ce 
(Uni
versi
ty 
of 
Edi
nburgh, 
UK)*; 
Margus 
Punab 
(Tartu 
Uni
versi
ty 
Cli
ni
cs, 
Estoni
a)*; 
Radwan 
F 
Qasrawi
 
(Al-Quds 
Uni
versi
ty, 
Palesti
ne)*; 
Mostafa 
Qorbani
 
(Alborz 
Uni
versi
ty 
of 
Medi
cal 
Sci
ences, 
Iran)*; 
Ri
cardas 
Radi
sauskas 
(Li
thuani
an 
Uni
versi
ty 
of 
Health 
Sci
ences, 
Li
thuani
a)*; 
Mahmudur 
Rahman 
(Insti
tute 
of 
Epi
demi
ology 
Di
sease 
Control 
and 
Research, 
Bangladesh)*; 
Olli
 
Rai
takari
 
(Uni
versi
ty 
of 
Turku, 
Fi
nland)*; 
Sudha 
Ramachandra 
Rao 
(Nati
onal 
Insti
tute 
of 
Epi
demi
ology, 
Indi
a)*; 
Ambady 
Ramachandran 
(Indi
a 
Di
abetes 
Research 
Foundati
on, 
Indi
a)*; 
Jacqueli
ne 
Ramke 
(Uni
versi
ty 
of 
New 
South 
Wales, 
Australi
a)*; 
Rafel 
Ramos 
(Insti
tut 
Uni
versi
tari
 
d’Investi
gaci
ó 
en 
Atenci
ó 
Pri
màri
a 
Jordi
 
Gol, 
Spai
n)*; 
Sanjay 
Rampal 
(Uni
versi
ty 
of 
Malaya, 
Malaysi
a)*; 
Wolfgang 
Rathmann 
(German 
Di
abetes 
Center, 
Germany)*; 
Josep 
Redon 
(Uni
versi
ty 
of 
Valenci
a, 
Spai
n)*; 
Paul 
Ferdi
nand 
M 
Regani
t 
(Uni
versi
ty 
of 
the 
Phi
li
ppi
nes, 
Phi
li
ppi
nes)*; 
Fernando 
Ri
go 
(Health 
Center 
San 
Agustí
n, 
Spai
n)*; 
Si
an 
M 
Robi
nson 
(Uni
versi
ty 
of 
Southampton, 
UK)*; 
Cynthi
a 
Robi
tai
lle 
(Publi
c 
Health 
Agency 
of 
Canada, 
Canada)*; 
Fernando 
Rodrí
guez-Artalejo 
(Uni
versi
dad 
Autónoma 
de 
Madri
d, 
Spai
n)*; 
Marí
a 
del 
Cri
sto 
Rodri
guez-Perez 
(Canari
an 
Health 
Servi
ce, 
Spai
n)*; 
Laura 
A 
Rodrí
guez-Vi
llami
zar 
(Uni
versi
dad 
Industri
al 
de 
Santander, 
Colombi
a)*; 
Rosalba 
Rojas-Marti
nez 
(Insti
tuto 
Naci
onal 
de 
Salud 
Públi
ca, 
Mexi
co)*; 
Ki
mmo 
Ronkai
nen 
(Uni
versi
ty 
of 
Eastern 
Fi
nland, 
Fi
nland)*; 
Anni
ka 
Rosengren 
(Uni
versi
ty 
of 
Gothenburg, 
Sweden)*; 
Adolfo 
Rubi
nstei
n 
(Insti
tute 
for 
Cli
ni
cal 
Eff
 
ecti
veness 
and 
Health 
Poli
cy, 
Argenti
na)*; 
Ornelas 
Rui
 
(Uni
versi
ty 
of 
Madei
ra, 
Portugal)*; 
Blanca 
Sandra 
Rui
z-Betancourt 
(Insti
tuto 
Mexi
cano 
del 
Seguro 
Soci
al, 
Mexi
co)*; 
Andrea 
RV 
Russo 
Hori
moto 
(Heart 
Insti
tute, 
Brazi
l)*; 
Marci
n 
Rutkowski
 
(Medi
cal 
Uni
versi
ty 
of 
Gdansk, 
Poland)*; 
Charumathi
 
Sabanayagam 
(Si
ngapore 
Eye 
Research 
Insti
tute, 
 Ar
t
i
c
l
es
1528 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
Si
ngapore)*; 
Harshpal 
S 
Sachdev 
(Si
taram 
Bharti
a 
Insti
tute 
of 
Sci
ence 
and 
Research, 
Indi
a)*; 
Olfa 
Sai
di
 
(Uni
versi
ty 
Tuni
s 
El 
Manar, 
Tuni
si
a)*; 
Si
bel 
Sakarya 
(Marmara 
Uni
versi
ty, 
Turkey)*; 
Benoi
t 
Salanave 
(French 
Insti
tute 
for 
Health 
Survei
llance, 
France)*; 
Jukka 
T 
Salonen 
(Uni
versi
ty 
of 
Helsi
nki
, 
Fi
nland)*; 
Massi
mo 
Salvetti
 
(Uni
versi
ty 
of 
Bresci
a, 
Italy)*; 
Jose 
Sánchez-Abanto 
(Nati
onal 
Insti
tute 
of 
Health, 
Peru)*; 
Di
ana 
Santos 
(Uni
versi
ty 
of 
Li
sbon, 
Portugal)*; 
Renata 
Nunes 
dos 
Santos 
(Uni
versi
ty 
of 
São 
Paulo 
Cli
ni
cs 
Hospi
tal, 
Brazi
l)*; 
Rute 
Santos 
(Uni
versi
ty 
of 
Porto, 
Portugal)*; 
Jouko 
L 
Sarami
es 
(South 
Kareli
a 
Soci
al 
and 
Health 
Care 
Di
stri
ct, 
Fi
nland)*; 
Lui
s 
B 
Sardi
nha 
(Uni
versi
ty 
of 
Li
sbon, 
Portugal)*; 
Ni
zal 
Sarrafzadegan 
(Isfahan 
Cardi
ovascular 
Research 
Center, 
Iran)*; 
Kai
-Uwe 
Saum 
(German 
Cancer 
Research 
Center, 
Germany)*; 
Marci
a 
Scazufca 
(Uni
versi
ty 
of 
São 
Paulo 
Cli
ni
cs 
Hospi
tal, 
Brazi
l)*; 
Herman 
Schargrodsky 
(Hospi
tal 
Itali
ano 
de 
Buenos 
Ai
res, 
Argenti
na)*; 
Chri
sta 
Schei
dt-Nave 
(Robert 
Koch 
Insti
tute, 
Germany)*; 
Aye 
Aye 
Sei
n 
(Mi
ni
stry 
of 
Health, 
Myanmar)*; 
Sanjb 
K 
Sharma 
(B 
P 
Koi
rala 
Insti
tute 
of 
Health 
Sci
ences, 
Nepal)*; 
Jonathan 
E 
Shaw 
(Baker 
IDI 
Heart 
and 
Di
abetes 
Insti
tute, 
Australi
a)*; 
Kenji
 
Shi
buya 
(The 
Uni
versi
ty 
of 
Tokyo, 
Japan)*; 
Youchan 
Shi
n 
(Si
ngapore 
Eye 
Research 
Insti
tute, 
Si
ngapore)*; 
Rahman 
Shi
ri
 
(Fi
nni
sh 
Insti
tute 
of 
Occupati
onal 
Health, 
Fi
nland)*; 
Rosalynn 
Si
antar 
(Si
ngapore 
Eye 
Research 
Insti
tute, 
Si
ngapore)*; 
Abla 
M 
Si
bai
 
(Ameri
can 
Uni
versi
ty 
of 
Bei
rut, 
Lebanon)*; 
Mary 
Si
mon 
(Indi
a 
Di
abetes 
Research 
Foundati
on, 
Indi
a)*; 
Judi
th 
Si
mons 
(St 
Vi
ncent’s 
Hospi
tal, 
Australi
a)*; 
Leon 
A 
Si
mons 
(Uni
versi
ty 
of 
New 
South 
Wales, 
Australi
a)*; 
Mi
chael 
Sjostrom 
(Karoli
nska 
Insti
tutet, 
Sweden)*; 
Jolanta 
Slowi
kowska-Hi
lczer 
(Medi
cal 
Uni
versi
ty 
of 
Łodz, 
Poland)*; 
Przemyslaw 
Slusarczyk 
(Internati
onal 
Insti
tute 
of 
Molecular 
and 
Cell 
Bi
ology, 
Poland)*; 
Li
am 
Smeeth 
(London 
School 
of 
Hygi
ene 
& 
Tropi
cal 
Medi
ci
ne, 
UK)*; 
Mari
eke 
B 
Sni
jder 
(Academi
c 
Medi
cal 
Center 
of 
Uni
versi
ty 
of 
Amsterdam, 
Netherlands)*; 
Hung-Kwan 
So 
(The 
Chi
nese 
Uni
versi
ty 
of 
Hong 
Kong, 
Chi
na)*; 
Eugène 
Sobngwi
 
(Uni
versi
ty 
of 
Yaoundé 
1, 
Cameroon)*; 
Stefan 
Söderberg 
(Umeå 
Uni
versi
ty, 
Sweden)*; 
Vi
ncenzo 
Solfri
zzi
 
(Uni
versi
ty 
of 
Bari
, 
Italy)*; 
Emi
ly 
Sonestedt 
(Lund 
Uni
versi
ty, 
Sweden)*; 
Ai
cha 
Soumare 
(Uni
versi
ty 
of 
Bordeaux, 
France)*; 
Jan 
A 
Staessen 
(Uni
versi
ty 
of 
Leuven, 
Belgi
um)*; 
Mari
a 
G 
Stathopoulou 
(INSERM, 
France)*; 
Jostei
n 
Steene-Johannessen 
(Norwegi
an 
School 
of 
Sport 
Sci
ences, 
Norway)*; 
Peter 
Stehle 
(Bonn 
Uni
versi
ty, 
Germany)*; 
Aryeh 
D 
Stei
n 
(Emory 
Uni
versi
ty, 
USA)*; 
Jochanan 
Stessman 
(Hadassah 
Uni
versi
ty 
Medi
cal 
Center, 
Israel)*; 
Dori
s 
Stöckl 
(Helmholtz 
Zentrum 
München, 
Germany)*; 
Jakub 
Stokwi
szewski
 
(Nati
onal 
Insti
tute 
of 
Hygi
ene, 
Poland)*; 
Kari
en 
Stronks 
(Uni
versi
ty 
of 
Amsterdam, 
Netherlands)*; 
Mari
a 
Wany 
Strufaldi
 
(Federal 
Uni
versi
ty 
of 
São 
Paulo, 
Brazi
l)*; 
Chi
en-An 
Sun 
(Fu 
Jen 
Catholi
c 
Uni
versi
ty, 
Tai
wan)*; 
Johan 
Sundström 
(Uppsala 
Uni
versi
ty, 
Sweden)*; 
Yn-Tz 
Sung 
(The 
Chi
nese 
Uni
versi
ty 
of 
Hong 
Kong, 
Chi
na)*; 
Pai
bul 
Suri
yawongpai
sal 
(Mahi
dol 
Uni
versi
ty, 
Thai
land)*; 
Rody 
G 
Sy 
(Uni
versi
ty 
of 
the 
Phi
li
ppi
nes, 
Phi
li
ppi
nes)*; 
E 
Shyong 
Tai
 
(Nati
onal 
Uni
versi
ty 
of 
Si
ngapore, 
Si
ngapore)*; 
Abdonas 
Tamosi
unas 
(Li
thuani
an 
Uni
versi
ty 
of 
Health 
Sci
ences, 
Li
thuani
a)*; 
Li
ne 
Tang 
(Research 
Centre 
for 
Preventi
on 
and 
Health, 
Denmark)*; 
Mohammed 
Tarawneh 
(Mi
ni
stry 
of 
Health, 
Jordan)*; 
Caroli
na 
B 
Tarqui
-Mamani
 
(Nati
onal 
Insti
tute 
of 
Health, 
Peru)*; 
Anne 
Taylor 
(The 
Uni
versi
ty 
of 
Adelai
de, 
Australi
a)*; 
Holger 
Theobald 
(Karoli
nska 
Insti
tutet, 
Sweden)*; 
Lutgarde 
Thi
js 
(Uni
versi
ty 
of 
Leuven, 
Belgi
um)*; 
Beti
na 
H 
Thuesen 
(Research 
Centre 
for 
Preventi
on 
and 
Health, 
Denmark)*; 
Hanna 
K 
Tolonen 
(Nati
onal 
Insti
tute 
for 
Health 
and 
Welfare, 
Fi
nland)*; 
Janne 
S 
Tolstrup 
(Uni
versi
ty 
of 
Southern 
Denmark, 
Denmark)*; 
Murat 
Topbas 
(Karadeni
z 
Techni
cal 
Uni
versi
ty, 
Turkey)*; 
Mati
es 
Torrent 
(IB-SALUT 
Area 
de 
Salut 
de 
Menorca, 
Spai
n)*; 
Pi
erre 
Trai
ssac 
(Insti
tut 
de 
Recherche 
pour 
le 
Développement, 
France)*; 
Oanh 
T 
H 
Tri
nh 
(Uni
versi
ty 
of 
Pharmacy 
and 
Medi
ci
ne 
of 
Ho 
Chi
 
Mi
nh 
Ci
ty, 
Vi
etnam)*; 
Marshall 
K 
Tulloch-Rei
d 
(The 
Uni
versi
ty 
of 
the 
West 
Indi
es, 
Jamai
ca)*; 
Tomi
-Pekka 
Tuomai
nen 
(Uni
versi
ty 
of 
Eastern 
Fi
nland, 
Fi
nland)*; 
Mari
a 
L 
Turley 
(Mi
ni
stry 
of 
Health, 
New 
Zealand)*; 
Chri
stophe 
Tzouri
o 
(Uni
versi
ty 
of 
Bordeaux, 
France)*; 
Peter 
Ueda 
(Harvard 
T 
H 
Chan 
School 
of 
Publi
c 
Health, 
USA)*; 
Flora 
A 
M 
Ukoli
 
(Meharry 
Medi
cal 
College, 
USA)*; 
Hanno 
Ulmer 
(Medi
cal 
Uni
versi
ty 
of 
Innsbruck, 
Austri
a)*; 
Hannu 
M 
T 
Uusi
talo 
(Tampere 
Uni
versi
ty 
Hospi
tal, 
Fi
nland)*; 
Gonzalo 
Valdi
vi
a 
(Ponti
fi
 
ci
a 
Uni
versi
dad 
Católi
ca 
de 
Chi
le, 
Chi
le)*; 
Damaski
ni
 
Valvi
 
(Harvard 
T 
H 
Chan 
School 
of 
Publi
c 
Health, 
USA)*; 
Leni
e 
van 
Rossem 
(Uni
versi
ty 
Medi
cal 
Center 
Utrecht, 
Netherlands)*; 
Irene 
GM 
van 
Valkengoed 
(Academi
c 
Medi
cal 
Center 
of 
Uni
versi
ty 
of 
Amsterdam, 
Netherlands)*; 
Di
rk 
Vanderschueren 
(Katholi
eke 
Uni
versi
tei
t 
Leuven, 
Belgi
um)*; 
Di
ego 
Vanuzzo 
(Centro 
di
 
Prevenzi
one 
Cardi
ovascolare 
Udi
ne, 
Italy)*; 
Tomas 
Vega 
(Consejerí
a 
de 
Sani
dad 
Junta 
de 
Casti
lla 
y 
León, 
Spai
n)*; 
Gustavo 
Velasquez-Melendez 
(Uni
versi
dade 
Federal 
de 
Mi
nas 
Gerai
s, 
Brazi
l)*; 
Gi
ovanni
 
Veronesi
 
(Uni
versi
ty 
of 
Insubri
a, 
Italy)*; 
W 
M 
Moni
que 
Verschuren 
(Nati
onal 
Insti
tute 
for 
Publi
c 
Health 
and 
the 
Envi
ronment, 
Netherlands)*; 
Roosmari
jn 
Verstraeten 
(Insti
tute 
of 
Tropi
cal 
Medi
ci
ne, 
Belgi
um)*; 
Luci
e 
Vi
et 
(Nati
onal 
Insti
tute 
for 
Publi
c 
Health 
and 
the 
Envi
ronment, 
Netherlands)*; 
Jesus 
Vi
oque 
(Uni
versi
dad 
Mi
guel 
Hernandez, 
Spai
n)*; 
Jyrki
 
K 
Vi
rtanen 
(Uni
versi
ty 
of 
Eastern 
Fi
nland, 
Fi
nland)*; 
Sophi
e 
Vi
svi
ki
s-Si
est 
(INSERM, 
France)*; 
Bharathi
 
Vi
swanathan 
(Mi
ni
stry 
of 
Health, 
Seychelles)*; 
Peter 
Vollenwei
der 
(Lausanne 
Uni
versi
ty 
Hospi
tal, 
Swi
tzerland)*; 
Sari
 
Vouti
lai
nen 
(Uni
versi
ty 
of 
Eastern 
Fi
nland, 
Fi
nland)*; 
Marti
ne 
Vri
jhei
d 
(Centre 
for 
Research 
i
n 
Envi
ronmental 
Epi
demi
ology, 
Spai
n)*; 
Ali
sha 
N 
Wade 
(Uni
versi
ty 
of 
the 
Wi
twatersrand, 
South 
Afri
ca)*; 
Ali
ne 
Wagner 
(Uni
versi
ty 
of 
Strasbourg, 
France)*; 
Janette 
Walton 
(Uni
versi
ty 
College 
Cork, 
Ireland)*; 
Wan 
Nazai
moon 
Wan 
Mohamud 
(Insti
tute 
for 
Medi
cal 
Research, 
Malaysi
a)*; 
Feng 
Wang 
(Peki
ng 
Uni
versi
ty 
Si
xth 
Hospi
tal, 
Chi
na)*; 
Mi
ng-Dong 
Wang 
(Publi
c 
Health 
Agency 
of 
Canada, 
Canada)*; 
Qi
an 
Wang 
(Xi
nji
ang 
Medi
cal 
Uni
versi
ty, 
Chi
na)*; 
Ya 
Xi
ng 
Wang 
(Bei
ji
ng 
Tongren 
Hospi
tal, 
Chi
na)*; 
S 
Goya 
Wannamethee 
(Uni
versi
ty 
College 
London, 
UK)*; 
Deepa 
Weerasekera 
(Mi
ni
stry 
of 
Health, 
New 
Zealand)*; 
Peter 
H 
Whi
ncup 
(St 
George’s, 
Uni
versi
ty 
of 
London, 
UK)*; 
Kurt 
Wi
dhalm 
(Medi
cal 
Uni
versi
ty 
of 
Vi
enna, 
Austri
a)*; 
Andrzej 
Wi
ecek 
(Medi
cal 
Uni
versi
ty 
of 
Si
lesi
a, 
Poland)*; 
Alet 
H 
Wi
jga 
(Nati
onal 
Insti
tute 
for 
Publi
c 
Health 
and 
the 
Envi
ronment, 
Netherlands)*; 
Rai
nford 
J 
Wi
lks 
(The 
Uni
versi
ty 
of 
the 
West 
Indi
es, 
Jamai
ca)*; 
Johann 
Wi
llei
t 
(Medi
cal 
Uni
versi
ty 
Innsbruck, 
Austri
a)*; 
Tom 
Wi
lsgaard 
(Ui
T 
The 
Arcti
c 
Uni
versi
ty 
of 
Norway, 
Norway)*; 
Bogdan 
Wojtyni
ak 
(Nati
onal 
Insti
tute 
of 
Hygi
ene, 
Poland)*; 
Ti
en 
Yi
n 
Wong 
(Duke-NUS 
Graduate 
Medi
cal 
School, 
Si
ngapore)*; 
Jean 
Woo 
(The 
Chi
nese 
Uni
versi
ty 
of 
Hong 
Kong, 
Chi
na)*; 
Mark 
Woodward 
(Uni
versi
ty 
of 
Sydney, 
Australi
a; 
Uni
versi
ty 
of 
Oxford, 
UK)*; 
Frederi
ck 
C 
Wu 
(Uni
versi
ty 
of 
Manchester, 
UK)*; 
Shou 
Li
ng 
Wu 
(Kai
luan 
General 
Hospi
tal, 
Chi
na)*; 
Hai
quan 
Xu 
(Insti
tute 
of 
Food 
and 
Nutri
ti
on 
Development 
of 
Mi
ni
stry 
of 
Agri
culture, 
Chi
na)*; 
Wei
li
 
Yan 
(Fudan 
Uni
versi
ty, 
Chi
na)*; 
Xi
aoguang 
Yang 
(Chi
nese 
Center 
for 
Di
sease 
Control 
and 
Preventi
on, 
Chi
na)*; 
Xi
ngwang 
Ye 
(Uni
versi
ty 
of 
Chi
nese 
Academy 
of 
Sci
ences, 
Chi
na)*; 
Aki
hi
ro 
Yoshi
hara 
(Ni
i
gata 
Uni
versi
ty, 
Japan)*; 
Novi
e 
O 
Younger-Coleman 
(The 
Uni
versi
ty 
of 
the 
West 
Indi
es, 
Jamai
ca)*; 
Sabi
na 
Zambon 
(Uni
versi
ty 
of 
Padova, 
Italy)*; 
Abdul 
Hami
d 
Zargar 
(Center 
for 
Di
abetes 
and 
Endocri
ne 
Care, 
Indi
a)*; 
Tomasz 
Zdrojewski
 
(Medi
cal 
Uni
versi
ty 
of 
Gdansk, 
Poland)*; 
Wenhua 
Zhao 
(Chi
nese 
Center 
for 
Di
sease 
Control 
and 
Preventi
on, 
Chi
na)*; 
Yi
ngfeng 
Zheng 
(Si
ngapore 
Eye 
Research 
Insti
tute, 
Si
ngapore)*; 
Juli
o 
Zuñi
ga 
Ci
sneros 
(Gorgas 
Memori
al 
Insti
tute 
of 
Publi
c 
Health, 
Panama)*.
Dec
l
ar
at
i
on 
of
 
i
nt
er
es
t
s
ME 
reports 
a 
chari
table 
grant 
from 
Youth 
Health 
Programme 
of 
AstraZeneca, 
outsi
de 
the 
submi
tted 
work. 
JAR 
reports 
personal 
fees 
from 
Tres 
Montes 
Lucchetti
 
and 
grants 
from 
Danone 
Mexi
co, 
outsi
de 
the 
submi
tted 
work. 
All 
other 
members 
of 
the 
Pooled 
Analysi
s 
and 
Wri
ti
ng 
Group 
declare 
no 
competi
ng 
i
nterests.
Ac
knowl
edgment
s
The 
study 
was 
funded 
by 
the 
Wellcome 
Trust. We 
thank 
Chri
sti
na 
Banks, 
Dheeya 
Ri
zmi
e, 
and 
Yasaman 
Vali
 
for 
assi
stance 
wi
th 
data 
extracti
on. 
We 
thank 
WHO 
country 
and 
regi
onal 
offi
 
 
ces 
and 
the 
World 
Heart 
Federati
on 
for 
support 
i
n 
data 
i
denti
fi
 
cati
on 
and 
access.
Ref
er
enc
es
 
1 
Global 
Burden 
of 
Metaboli
c 
Ri
sk 
Factors 
for 
Chroni
c 
Di
seases 
Collaborati
on. 
Cardi
ovascular 
di
sease, 
chroni
c 
ki
dney 
di
sease, 
and 
di
abetes 
mortali
ty 
burden 
of 
cardi
ometaboli
c 
ri
sk 
factors 
from 
1980 
to 
2010:
 
a 
comparati
ve 
ri
sk 
assessment. 
Lanc
e
t
 
Di
abe
t
e
s
 
Endoc
r
i
nol
 
2014; 
2: 
634–47
.
 
2 
Seuri
ng 
T, 
Archangeli
di
 
O, 
Suhrcke 
M. 
The 
economi
c 
costs 
of 
type 
2 
di
abetes:
 
a 
global 
systemati
c 
revi
ew. 
Phar
mac
oe
c
onomi
c
s
 
2015; 
33: 
811–31.
 Ar
t
i
c
l
es
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016 
1529
 
3 
WHO. 
Global 
acti
on 
plan 
for 
the 
preventi
on 
and 
control 
of 
noncommuni
cable 
di
seases 
2013–2020. 
2013. 
http:
/
/
apps.who.i
nt/
i
ri
s/
bi
tstream/
10665/
94384/
1/
9789241506236_eng.pdf?
ua=1 
(accessed 
Aug 
14, 
2015).
 
4 
Danaei
 
G, 
Fi
nucane 
MM, 
Lu 
Y, 
et 
al. 
Nati
onal, 
regi
onal, 
and 
global 
trends 
i
n 
fasti
ng 
plasma 
glucose 
and 
di
abetes 
prevalence 
si
nce 
1980:
 
systemati
c 
analysi
s 
of 
health 
exami
nati
on 
surveys 
and 
epi
demi
ologi
cal 
studi
es 
wi
th 
370 
country-years 
and 
2·7 
mi
lli
on 
parti
ci
pants. 
Lanc
e
t
 
2011; 
378: 
31–40.
 
5 
Guari
guata 
L, 
Whi
ti
ng 
DR, 
Hambleton 
I, 
Beagley 
J, 
Li
nnenkamp 
U, 
Shaw 
JE. 
Global 
esti
mates 
of 
di
abetes 
prevalence 
for 
2013 
and 
projecti
ons 
for 
2035. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2014; 
1
03: 
137–49.
 
6 
Internati
onal 
Di
abetes 
Federati
on. 
IDF 
Di
abetes 
Atlas, 
6th 
edn. 
Brussels:
 
Internati
onal 
Di
abetes 
Federati
on, 
2013.
 
7 
Guari
guata 
L, 
Whi
ti
ng 
D, 
Wei
l 
C, 
Unwi
n 
N. 
The 
Internati
onal 
Di
abetes 
Federati
on 
Di
abetes 
Atlas 
methodology 
for 
esti
mati
ng 
global 
and 
nati
onal 
prevalence 
of 
di
abetes 
i
n 
adults. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2011; 
94: 
322–32.
 
8 
NCD 
Ri
sk 
Factor 
Collaborati
on. 
Eff
 
ects 
of 
di
abetes 
defi
 
ni
ti
on 
on 
global 
survei
llance 
of 
di
abetes 
prevalence 
and 
di
agnosi
s:
 
a 
pooled 
analysi
s 
of 
96 
populati
on-based 
studi
es 
wi
th 
331 
288 
parti
ci
pants. 
Lanc
e
t
 
Di
abe
t
e
s
 
Endoc
r
i
nol
 
2015; 
3: 
624–37
.
 
9 
Beagley 
J, 
Guari
guata 
L, 
Wei
l 
C, 
Motala 
AA. 
Global 
esti
mates 
of 
undi
agnosed 
di
abetes 
i
n 
adults. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2014; 
1
03: 
150–60.
 
10 Zhang 
X, 
Gei
ss 
LS, 
Cheng 
YJ, 
Beckles 
GL, 
Gregg 
EW, 
Kahn 
HS. 
The 
mi
ssed 
pati
ent 
wi
th 
di
abetes:
 
how 
access 
to 
health 
care 
aff
 
ects 
the 
detecti
on 
of 
di
abetes. 
Di
abe
t
e
s
 
Car
e
 
2008; 
31
: 
1748–53.
 
11 Gaki
dou 
E, 
Malli
nger 
L, 
Abbott-Klafter 
J, 
et 
al. 
Management 
of 
di
abetes 
and 
associ
ated 
cardi
ovascular 
ri
sk 
factors 
i
n 
seven 
countri
es:
 
a 
compari
son 
of 
data 
from 
nati
onal 
health 
exami
nati
on 
surveys. 
Bul
l
 
Wor
l
d 
He
al
t
h 
Or
gan 
2011; 
89: 
172–83.
 
12 Fi
nucane 
MM, 
Paci
orek 
CJ, 
Danaei
 
G, 
Ezzati
 
M. 
Bayesi
an 
esti
mati
on 
of 
populati
on-level 
trends 
i
n 
measures 
of 
health 
status. 
St
at
 
Sc
i
 
2014; 
29: 
18–25.
 
13 Danaei
 
G, 
Fi
nucane 
MM, 
Li
n 
JK, 
et 
al. 
Nati
onal, 
regi
onal, 
and 
global 
trends 
i
n 
systoli
c 
blood 
pressure 
si
nce 
1980:
 
systemati
c 
analysi
s 
of 
health 
exami
nati
on 
surveys 
and 
epi
demi
ologi
cal 
studi
es 
wi
th 
786 
country-years 
and 
5·4 
mi
lli
on 
parti
ci
pants. 
Lanc
e
t
 
2011; 
377: 
568–77
.
 
14 Stevens 
GA, 
Bennett 
JE, 
Hennocq 
Q, 
et 
al. 
Trends 
and 
mortali
ty 
eff
 
ects 
of 
vi
tami
n 
A 
defi
 
ci
ency 
i
n 
chi
ldren 
i
n 
138 
low-i
ncome 
and 
mi
ddle-i
ncome 
countri
es 
between 
1991 
and 
2013:
 
a 
pooled 
analysi
s 
of 
populati
on-based 
surveys. 
Lanc
et
 
Gl
ob 
Heal
t
h 
2015; 
3: 
e528–36.
 
15 Si
ngh 
GM, 
Danaei
 
G, 
Peli
zzari
 
PM, 
et 
al. 
The 
age 
associ
ati
ons 
of 
blood 
pressure, 
cholesterol, 
and 
glucose:
 
analysi
s 
of 
health 
exami
nati
on 
surveys 
from 
i
nternati
onal 
populati
ons. 
Ci
r
c
ul
at
i
on 
2012; 
1
25: 
2204–11.
 
16 NCD 
Ri
sk 
Factor 
Collaborati
on 
(NCD-Ri
sC). 
Trends 
i
n 
adult 
body-mass 
i
ndex 
i
n 
200 
countri
es 
from 
1975 
to 
2014:
 
a 
pooled 
analysi
s 
of 
1698 
populati
on-based 
measurement 
studi
es 
wi
th 
19·2 
mi
lli
on 
parti
ci
pants. 
Lanc
e
t
 
2016; 
387: 1377–96.
 
17 Ezzati
 
M, 
Ri
boli
 
E. 
Behavi
oral 
and 
di
etary 
ri
sk 
factors 
for 
noncommuni
cable 
di
seases. 
N 
Engl
 
J
 
Me
d 
2013; 
369: 
954–64.
 
18 Wandell 
PE, 
Carlsson 
AC. 
Gender 
di
ff
 
erences 
and 
ti
me 
trends 
i
n 
i
nci
dence 
and 
prevalence 
of 
type 
2 
di
abetes 
i
n 
Sweden--a 
model 
explai
ni
ng 
the 
di
abetes 
epi
demi
c 
worldwi
de 
today?
 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2014; 
1
06: 
e90–92.
 
19 Gale 
EA, 
Gi
llespi
e 
KM. 
Di
abetes 
and 
gender. 
Di
abe
t
ol
ogi
a 
2001; 
44: 
3–15.
 
20 Hwang 
CK, 
Han 
PV, 
Zabeti
an 
A, 
Ali
 
MK, 
Narayan 
KM. 
Rural 
di
abetes 
prevalence 
qui
ntuples 
over 
twenty-fi
 
ve 
years 
i
n 
low- 
and 
mi
ddle-i
ncome 
countri
es:
 
a 
systemati
c 
revi
ew 
and 
meta-analysi
s. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2012; 
96: 
271–85.
 
21 A 
mass 
survey 
of 
di
abetes 
melli
tus 
i
n 
a 
populati
on 
of 
300,000 
i
n 
14 
provi
nces 
and 
muni
ci
pali
ti
es 
i
n 
Chi
na 
(author’s 
transl). 
Zhonghua 
Ne
i
 
Ke
 
Za 
Zhi
 
1981; 
20: 
678–83 
(i
n 
Chi
nese).
 
22 Eli
asson 
M, 
Li
ndahl 
B, 
Lundberg 
V, 
Stegmayr 
B. 
No 
i
ncrease 
i
n 
the 
prevalence 
of 
known 
di
abetes 
between 
1986 
and 
1999 
i
n 
subjects 
25–64 
years 
of 
age 
i
n 
northern 
Sweden. 
Di
abe
t
 
Me
d 
2002; 
1
9: 
874–80.
 
23 Icks 
A, 
Moebus 
S, 
Feuersenger 
A, 
Haastert 
B, 
Jockel 
KH, 
Gi
ani
 
G. 
Di
abetes 
prevalence 
and 
associ
ati
on 
wi
th 
soci
al 
status--wi
deni
ng 
of 
a 
soci
al 
gradi
ent?
 
German 
nati
onal 
health 
surveys 
1990–1992 
and 
1998. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2007; 
78: 
293–97
.
 
24 Teuscher 
AU, 
Di
em 
P, 
Thomas 
W, 
Janett 
J, 
Teuscher 
A. 
Inci
dence 
of 
i
nsuli
n-dependent 
di
abetes 
melli
tus 
i
n 
Swi
tzerland 
(1972–1993) 
i
n 
19-year-old 
men. 
Sc
hwe
i
z 
Me
d 
Woc
he
ns
c
hr
 
1995; 
1
25: 
1041–45 
(i
n 
German).
 
25 Menke 
A, 
Casagrande 
S, 
Gei
ss 
L, 
Cowi
e 
CC. 
Prevalence 
of 
and 
trends 
i
n 
di
abetes 
among 
adults 
i
n 
the 
Uni
ted 
States, 
1988–2012. 
J
AMA 
2015; 
31
4: 
1021–29.
 
26 Imkampe 
AK, 
Gulli
ford 
MC. 
Increasi
ng 
soci
o-economi
c 
i
nequali
ty 
i
n 
type 
2 
di
abetes 
prevalence--repeated 
cross-secti
onal 
surveys 
i
n 
England 
1994–2006. 
Eur
 
J
 
Publ
i
c
 
He
al
t
h 
2011; 
21
: 
484–90.
 
27 Hamer 
M, 
Kengne 
AP, 
Batty 
GD, 
Cooke 
D, 
Stamataki
s 
E. 
Temporal 
trends 
i
n 
di
abetes 
prevalence 
and 
key 
di
abetes 
ri
sk 
factors 
i
n 
Scotland, 
2003–2008. 
Di
abe
t
 
Me
d 
2011; 
28: 
595–98.
 
28 Charvat 
H, 
Goto 
A, 
Goto 
M, 
et 
al. 
Impact 
of 
populati
on 
agi
ng 
on 
trends 
i
n 
di
abetes 
prevalence:
 
A 
meta-regressi
on 
analysi
s 
of 
160,000 
Japanese 
adults. 
J
 
Di
abe
t
e
s
 
Inve
s
t
i
g 
2015; 
6: 
533–42.
 
29 Li
 
MZ, 
Su 
L, 
Li
ang 
BY, 
et 
al. 
Trends 
i
n 
prevalence, 
awareness, 
treatment, 
and 
control 
of 
di
abetes 
melli
tus 
i
n 
mai
nland 
Chi
na 
from 
1979 
to 
2012. 
Int
 
J
 
Endoc
r
i
nol
 
2013; 
201
3:
 
753150.
 
30 Zuo 
H, 
Shi
 
Z, 
Hussai
n 
A. 
Prevalence, 
trends 
and 
ri
sk 
factors 
for 
the 
di
abetes 
epi
demi
c 
i
n 
Chi
na:
 
a 
systemati
c 
revi
ew 
and 
meta-analysi
s. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2014; 
1
04: 
63–72.
 
31 Jayawardena 
R, 
Ranasi
nghe 
P, 
Byrne 
NM, 
Soares 
MJ, 
Katulanda 
P, 
Hi
lls 
AP. 
Prevalence 
and 
trends 
of 
the 
di
abetes 
epi
demi
c 
i
n 
South 
Asi
a:
 
a 
systemati
c 
revi
ew 
and 
meta-analysi
s. 
BMC 
Publ
i
c
 
He
al
t
h 
2012; 
1
2:
 
380.
 
32 Mi
sra 
P, 
Upadhyay 
RP, 
Mi
sra 
A, 
Anand 
K. 
A 
revi
ew 
of 
the 
epi
demi
ology 
of 
di
abetes 
i
n 
rural 
Indi
a. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2011; 
92: 
303–11.
 
33 Mohan 
V, 
Deepa 
M, 
Deepa 
R, 
et 
al. 
Secular 
trends 
i
n 
the 
prevalence 
of 
di
abetes 
and 
i
mpai
red 
glucose 
tolerance 
i
n 
urban 
South 
Indi
a—the 
Chennai
 
Urban 
Rural 
Epi
demi
ology 
Study 
(CURES-17). 
Di
abe
t
ol
ogi
a 
2006; 
49: 
1175–78.
 
34 Ramachandran 
A, 
Snehalatha 
C, 
Shetty 
AS, 
Nandi
tha 
A. 
Trends 
i
n 
prevalence 
of 
di
abetes 
i
n 
Asi
an 
countri
es. 
Wor
l
d 
J
 
Di
abe
t
e
s
 
2012; 
3: 
110–17
.
 
35 Esteghamati
 
A, 
Etemad 
K, 
Koohpayehzadeh 
J, 
et 
al. 
Trends 
i
n 
the 
prevalence 
of 
di
abetes 
and 
i
mpai
red 
fasti
ng 
glucose 
i
n 
associ
ati
on 
wi
th 
obesi
ty 
i
n 
Iran:
 
2005–2011. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2014; 
1
03: 
319–27
.
 
36 Satman 
I, 
Omer 
B, 
Tutuncu 
Y, 
et 
al. 
Twelve-year 
trends 
i
n 
the 
prevalence 
and 
ri
sk 
factors 
of 
di
abetes 
and 
predi
abetes 
i
n 
Turki
sh 
adults. 
Eur
 
J
 
Epi
de
mi
ol
 
2013; 
28: 
169–80.
 
37 Alharbi
 
NS, 
Almutari
 
R, 
Jones 
S, 
Al-Daghri
 
N, 
Khunti
 
K, 
de 
Lusi
gnan 
S. 
Trends 
i
n 
the 
prevalence 
of 
type 
2 
di
abetes 
melli
tus 
and 
obesi
ty 
i
n 
the 
Arabi
an 
Gulf 
States:
 
systemati
c 
revi
ew 
and 
meta-analysi
s. 
Di
abe
t
e
s
 
Re
s
 
Cl
i
n 
Pr
ac
t
 
2014; 
1
06: 
e30–33.
 
38 Hales 
CN, 
Barker 
DJ. 
Type 
2 
(non-i
nsuli
n-dependent) 
di
abetes 
melli
tus:
 
the 
thri
fty 
phenotype 
hypothesi
s. 
Di
abe
t
ol
ogi
a 
1992; 
35: 
595–601.
 
39 Chambers 
JC, 
Zhang 
W, 
Zabaneh 
D, 
et 
al. 
Common 
geneti
c 
vari
ati
on 
near 
melatoni
n 
receptor 
MTNR1B 
contri
butes 
to 
rai
sed 
plasma 
glucose 
and 
i
ncreased 
ri
sk 
of 
type 
2 
di
abetes 
among 
Indi
an 
Asi
ans 
and 
European 
Caucasi
ans. 
Di
abe
t
e
s
 
2009; 
58: 
2703–08.
 
40 Ramachandran 
A, 
Ma 
RC, 
Snehalatha 
C. 
Di
abetes 
i
n 
Asi
a. 
Lanc
e
t
 
2010; 
375: 
408–18.
 
41 Bhargava 
SK, 
Sachdev 
HS, 
Fall 
CH, 
et 
al. 
Relati
on 
of 
seri
al 
changes 
i
n 
chi
ldhood 
body-mass 
i
ndex 
to 
i
mpai
red 
glucose 
tolerance 
i
n 
young 
adulthood. 
N 
Engl
 
J
 
Me
d 
2004; 
350: 
865–75.
 
42 Chan 
JC, 
Mali
k 
V, 
Ji
a 
W, 
et 
al. 
Di
abetes 
i
n 
Asi
a:
 
epi
demi
ology, 
ri
sk 
factors, 
and 
pathophysi
ology. 
J
AMA 
2009; 
301
: 
2129–40.
 
43 Colagi
uri
 
R, 
Colagi
uri
 
S, 
Yach 
D, 
Prammi
ng 
S. 
The 
answer 
to 
di
abetes 
preventi
on:
 
sci
ence, 
surgery, 
servi
ce 
deli
very, 
or 
soci
al 
poli
cy?
 
Am 
J
 
Publ
i
c
 
He
al
t
h 
2006; 
96: 
1562–69.
 
44 Knowler 
WC, 
Barrett-Connor 
E, 
Fowler 
SE, 
et 
al. 
Reducti
on 
i
n 
the 
i
nci
dence 
of 
type 
2 
di
abetes 
wi
th 
li
festyle 
i
nterventi
on 
or 
metformi
n. 
N 
Engl
 
J
 
Me
d 
2002; 
346: 
393–403.
 Ar
t
i
c
l
es
1530 
www.
t
helancet
.
com 
  Vol
 
387 
 
 
Apr
i
l
 
9, 
2016
 
45 Farzadfar 
F, 
Murray 
CJ, 
Gaki
dou 
E, 
et 
al. 
Eff
 
ecti
veness 
of 
di
abetes 
and 
hypertensi
on 
management 
by 
rural 
pri
mary 
health-care 
workers 
(Behvarz 
workers) 
i
n 
Iran:
 
a 
nati
onally 
representati
ve 
observati
onal 
study. 
Lanc
e
t
 
2012; 
379: 
47–54.
 
46 Ley 
SH, 
Hamdy 
O, 
Mohan 
V, 
Hu 
FB. 
Preventi
on 
and 
management 
of 
type 
2 
di
abetes:
 
di
etary 
components 
and 
nutri
ti
onal 
strategi
es. 
Lanc
e
t
 
2014; 
383: 
1999–2007
.
 
47 Sutheran 
HL, 
Reynolds 
T. 
Techni
cal 
and 
cli
ni
cal 
accuracy 
of 
three 
blood 
glucose 
meters:
 
cli
ni
cal 
i
mpact 
assessment 
usi
ng 
error 
gri
d 
analysi
s 
and 
i
nsuli
n 
sli
di
ng 
scales. 
J
 
Cl
i
n 
Pat
hol
 
2016; 
publi
shed 
onli
ne 
Feb 
5. 
DOI:
 
10.1136/
jcli
npath-2015-203339.
 
48 Pfutzner 
A, 
Mi
tri
 
M, 
Musholt 
PB, 
et 
al. 
Cli
ni
cal 
assessment 
of 
the 
accuracy 
of 
blood 
glucose 
measurement 
devi
ces. 
Cur
r
 
Me
d 
Re
s
 
Opi
n 
2012; 
28: 
525–31.
 
49 Di
az-Valenci
a 
PA, 
Bougneres 
P, 
Valleron 
AJ. 
Global 
epi
demi
ology 
of 
type 
1 
di
abetes 
i
n 
young 
adults 
and 
adults:
 
a 
systemati
c 
revi
ew. 
BMC 
Publ
i
c
 
He
al
t
h 
2015; 
1
5: 
255.
 
50 Tuomi
lehto 
J. 
The 
emergi
ng 
global 
epi
demi
c 
of 
type 
1 
di
abetes. 
Cur
r
 
Di
ab 
Re
p 
2013; 
1
3: 
795–804.
 
51 Ameri
can 
Di
abetes 
Associ
ati
on. 
Di
agnosi
s 
and 
classi
fi
 
cati
on 
of 
di
abetes 
melli
tus. 
Di
abe
t
e
s
 
Car
e
 
2004; 
27 (suppl 
1): 
S5–10.
 
52 Centers 
for 
Di
sease 
Control 
and 
Preventi
on. 
Nati
onal 
di
abetes 
stati
sti
cs 
report:
 
esti
mates 
of 
di
abetes 
and 
i
ts 
burden 
i
n 
the 
Uni
ted 
States, 
2014. 
Atlanta, 
GA:
 
US 
Department 
of 
Health 
and 
Human 
Servi
ces, 
2014.
 
53 Global 
Burden 
of 
Di
sease 
Study 
Collaborators. 
Global, 
regi
onal, 
and 
nati
onal 
i
nci
dence, 
prevalence, 
and 
years 
li
ved 
wi
th 
di
sabi
li
ty 
for 
301 
acute 
and 
chroni
c 
di
seases 
and 
i
njuri
es 
i
n 
188 
countri
es, 
1990–2013:
 
a 
systemati
c 
analysi
s 
for 
the 
Global 
Burden 
of 
Di
sease 
Study 
2013. 
Lanc
e
t
 
2015; 
386: 
743–800.
 
54 Pan 
SC, 
Ku 
CC, 
Kao 
D, 
Ezzati
 
M, 
Fang 
CT, 
Li
n 
HH. 
Eff
 
ect 
of 
di
abetes 
on 
tuberculosi
s 
control 
i
n 
13 
countri
es 
wi
th 
hi
gh 
tuberculosi
s:
 
a 
modelli
ng 
study. 
Lanc
e
t
 
Di
abe
t
e
s
 
Endoc
r
i
nol
 
2015; 
3: 
323–30.
 
55 Holman 
RR, 
Paul 
SK, 
Bethel 
MA, 
Matthews 
DR, 
Nei
l 
HA. 
10-year 
follow-up 
of 
i
ntensi
ve 
glucose 
control 
i
n 
type 
2 
di
abetes. 
N 
Engl
 
J
 
Me
d 
2008; 
359: 
1577–89.
 
56 The 
ADVANCE 
Collaborati
ve 
Group. 
Intensi
ve 
blood 
glucose 
control 
and 
vascular 
outcomes 
i
n 
pati
ents 
wi
th 
type 
2 
di
abetes. 
N 
Engl
 
J
 
Me
d 
2008; 
358: 
2560–72.
 
57 The 
Look 
AHEAD 
Research 
Group. 
Eff
 
ect 
of 
a 
long-term 
behavi
oural 
wei
ght 
loss 
i
nterventi
on 
on 
nephropathy 
i
n 
overwei
ght 
or 
obese 
adults 
wi
th 
type 
2 
di
abetes:
 
a 
secondary 
analysi
s 
of 
the 
Look 
AHEAD 
randomi
sed 
cli
ni
cal 
tri
al. 
Lanc
e
t
 
Di
abe
t
e
s
 
Endoc
r
i
nol
 
2014; 
2: 
801–09.
 
58 Holman 
RR, 
Souri
j 
H, 
Cali
ff
 
 
RM. 
Cardi
ovascular 
outcome 
tri
als 
of 
glucose-loweri
ng 
drugs 
or 
strategi
es 
i
n 
type 
2 
di
abetes. 
Lanc
e
t
 
2014; 
383: 
2008–17
.
 
59 Skyler 
JS, 
Bergenstal 
R, 
Bonow 
RO, 
et 
al. 
Intensi
ve 
glycemi
c 
control 
and 
the 
preventi
on 
of 
cardi
ovascular 
events:
 
i
mpli
cati
ons 
of 
the 
ACCORD, 
ADVANCE, 
and 
VA 
di
abetes 
tri
als:
 
a 
posi
ti
on 
statement 
of 
the 
Ameri
can 
Di
abetes 
Associ
ati
on 
and 
a 
sci
enti
fi
 
c 
statement 
of 
the 
Ameri
can 
College 
of 
Cardi
ology 
Foundati
on 
and 
the 
Ameri
can 
Heart 
Associ
ati
on. 
Ci
r
c
ul
at
i
on 
2009; 
1
1
9: 
351–57
.
 
60 Cefalu 
WT. 
Glycemi
c 
targets 
and 
cardi
ovascular 
di
sease. 
N 
Engl
 
J
 
Me
d 
2008; 
358: 
2633–35.
 
61 Gaede 
P, 
Vedel 
P, 
Larsen 
N, 
Jensen 
GV, 
Parvi
ng 
HH, 
Pedersen 
O. 
Multi
factori
al 
i
nterventi
on 
and 
cardi
ovascular 
di
sease 
i
n 
pati
ents 
wi
th 
type 
2 
di
abetes. 
N 
Engl
 
J
 
Me
d 
2003; 
348: 
383–93.
 
62 Fox 
CS, 
Golden 
SH, 
Anderson 
C, 
et 
al. 
Update 
on 
preventi
on 
of 
cardi
ovascular 
di
sease 
i
n 
adults 
wi
th 
type 
2 
di
abetes 
melli
tus 
i
n 
li
ght 
of 
recent 
evi
dence:
 
a 
sci
enti
fi
 
c 
statement 
from 
the 
Ameri
can 
Heart 
Associ
ati
on 
and 
the 
Ameri
can 
Di
abetes 
Associ
ati
on. 
Ci
r
c
ul
at
i
on 
2015; 
1
32: 
691–718.
 
63 Ali
 
MK, 
Bullard 
KM, 
Saaddi
ne 
JB, 
Cowi
e 
CC, 
Imperatore 
G, 
Gregg 
EW. 
Achi
evement 
of 
goals 
i
n 
U.S. 
di
abetes 
care, 
1999–2010. 
N 
Engl
 
J
 
Me
d 
2013; 
368: 
1613–24.
 
64 Gregg 
EW, 
Albri
ght 
AL. 
The 
publi
c 
health 
response 
to 
di
abetes--two 
steps 
forward, 
one 
step 
back. 
J
AMA 
2009; 
301
: 
1596–98.
 
65 Gregg 
EW, 
Li
 
Y, 
Wang 
J, 
et 
al. 
Changes 
i
n 
di
abetes-related 
compli
cati
ons 
i
n 
the 
Uni
ted 
States, 
1990–2010. 
N 
Engl
 
J
 
Me
d 
2014; 
370: 
1514–23.
 
66 Tuomi
lehto 
J, 
Li
ndstrom 
J, 
Eri
ksson 
JG, 
et 
al. 
Preventi
on 
of 
type 
2 
di
abetes 
melli
tus 
by 
changes 
i
n 
li
festyle 
among 
subjects 
wi
th 
i
mpai
red 
glucose 
tolerance. 
N 
Engl
 
J
 
Me
d 
2001; 
344: 
1343–50.
 
67 Ramachandran 
A, 
Snehalatha 
C, 
Mary 
S, 
et 
al. 
The 
Indi
an 
Di
abetes 
Preventi
on 
Programme 
shows 
that 
li
festyle 
modi
fi
 
cati
on 
and 
metformi
n 
prevent 
type 
2 
di
abetes 
i
n 
Asi
an 
Indi
an 
subjects 
wi
th 
i
mpai
red 
glucose 
tolerance 
(IDPP-1). 
Di
abe
t
ol
ogi
a 
2006; 
49: 
289–97
.
 
68 Saari
sto 
T, 
Moi
lanen 
L, 
Korpi
-Hyovalti
 
E, 
et 
al. 
Li
festyle 
i
nterventi
on 
for 
preventi
on 
of 
type 
2 
di
abetes 
i
n 
pri
mary 
health 
care:
 
one-year 
follow-up 
of 
the 
Fi
nni
sh 
Nati
onal 
Di
abetes 
Preventi
on 
Program 
(FIN-D2D). 
Di
abe
t
e
s
 
Car
e
 
2010; 
33: 
2146–51.
 
69 DePue 
JD, 
Dunsi
ger 
S, 
Sei
den 
AD, 
et 
al. 
Nurse-communi
ty 
health 
worker 
team 
i
mproves 
di
abetes 
care 
i
n 
Ameri
can 
Samoa:
 
results 
of 
a 
randomi
zed 
controlled 
tri
al. 
Di
abe
t
e
s
 
Car
e
 
2013; 
36: 
1947–53.
 
70 Narayan 
KM, 
Echouff
 
o-Tcheugui
 
JB, 
Mohan 
V, 
Ali
 
MK. 
Analysi
s 
& 
commentary:
 
global 
preventi
on 
and 
control 
of 
type 
2 
di
abetes 
wi
ll 
requi
re 
paradi
gm 
shi
fts 
i
n 
poli
ci
es 
wi
thi
n 
and 
among 
countri
es. 
He
al
t
h 
Aff
 
 
(Mi
l
l
wood) 
2012; 
31
: 
84–92.
